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Studies show that individuals with subacute and chronic stroke in inpatient rehabilitation 
facilities and living in the community engage in very little physical activity.  Furthermore, people 
post-stroke have been shown to have low aerobic fitness (peak VO2).  Lack of physical activity 
and reduced aerobic fitness in individuals with stroke may affect their ability to ambulate and 
perform basic activities of daily living (ADLs).  Evidence suggests that greater amounts of time 
spent in bed during inpatient rehabilitation is associated with poorer outcome on the modified 
Rankin Scale (mRS), a measure of functional independence, at three months post-stroke.  
However, no studies in the United States have objectively quantified the amount of activity 
performed in individuals with acute stroke and how sedentary time relates to functional ability at 
discharge from the hospital.  This information is important for clinical practice in understanding 
how physical activity and exercise influence recovery after stroke. 
Moreover, in order to gain a more in-depth understanding of the potential benefits of 
physical activity, aerobic fitness, and exercise, we need to evaluate the response of potential 
neuroprotective factors after stroke that are influenced by modifiable lifestyle factors, such as 
aerobic fitness and physical activity.  Insulin-like growth factor-1 (IGF-1), a known 
neuroprotective agent in animal models, may be among the possible growth factors influenced by 
lifestyle that are vital to recovery.  When IGF-1 is administered by intranasal delivery, core 
stroke lesion size can be reduced up to 94%, while also improving functional status, compared to 
vehicle controls.  In addition, both circulating levels of IGF-1 and IGFBP-3 can be influenced by 
physical activity and aerobic fitness in healthy individuals.  Therefore, research is needed to 
better characterize physical activity levels and understand the interaction between physical 
activity levels, aerobic fitness, and IGF-1 response in individuals with acute stroke. The goal of 
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the work undertaken in this dissertation is to quantify physical activity levels and determine the 
relationship between IGF-1 response, estimated aerobic fitness, and stroke outcomes following 
an acute stroke in humans. 
In order to achieve our goal, we first set out to objectively quantify physical activity 
levels in individuals with acute stroke and examine the relationship between sedentary time 
during the hospital stay and functional performance at discharge.  In Chapter 2, our investigation 
of 32 individuals showed that individuals with acute stroke spent a large majority of time 
sedentary during their hospital stay.  Sedentary time was positively related to the Physical 
Performance Test, even when controlling for baseline performance.  This suggests that 
individuals who spent more hospital time sedentary performed worse on functional tasks prior to 
discharge, regardless of their performance at baseline.  These results demonstrate that people 
recovering from stroke spend most of their hospital stay sedentary.  This may have important 
implications for stroke recovery. 
Next, because physical activity is directly related to aerobic fitness and previous literature 
suggests that aerobic fitness is diminished in individuals with subacute and chronic stroke, in 
Chapter 3 we set out to examine whether estimated pre-stroke peak VO2 was related to function 
at hospital discharge.  Our results suggest that non-exercise estimation of pre-stroke peak VO2 is 
easily administered within 48 hours of hospital admission in individuals with acute stroke.  
Analysis of the relationship between estimated pre-stroke peak VO2 and functional performance 
at discharge revealed no significant relationships when considering the total sample.  However, 
when stratifying the sample by gender, significant relationships were observed in females 
between estimated pre-stroke peak VO2 and the Fugl-Meyer Assessment of lower extremity 
motor function.  Females with higher aerobic fitness prior to stroke exhibited better motor 
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function of the lower extremities at discharge from the hospital.  However, no significant 
relationships were observed for men.  Therefore, estimations of pre-stroke peak VO2 are feasible 
to use in individuals during the acute hospital setting.  The results of this investigation provide 
important information for future studies for characterizing fitness prior to stroke and how it may 
relate to objective measures of physical function during stroke recovery and neuroprotective 
markers such as IGF-1. 
Further, because current literature suggests that IGF-1 is neuroprotective after stroke and in 
healthy individuals, IGF-1 levels can be influenced by physical activity and aerobic fitness, in 
Chapter 4 we set out to examine IGF-1 and its relationship to estimated pre-stroke peak VO2 
levels in individuals with acute stroke.  The results indicate that in 15 individuals with acute 
stroke, estimated pre-stroke peak VO2 is significantly related to circulating IGF-1 levels obtained 
within 72 hours of hospital admission.  Individuals with higher than median IGF-1 levels 
possessed significantly better aerobic fitness prior to their stroke.  These results suggest that 
improving aerobic fitness prior to stroke may be beneficial and provide neuroprotection by 
increasing baseline IGF-1 levels. 
Finally, many studies have seen that individuals with high IGF-1 levels soon after stroke 
have a greater chance at survival and more independence 3 months later.  However, these studies 
may have a limited understanding of IGF-1’s neuroprotective qualities because they do not 
consider how the response of IGF-1 during the first weeks of stroke is important and only use 
general questionnaires to assess outcomes.  Therefore, Chapter 5 aimed to characterize the 
response of IGF-1 during the first week of stroke and how it may be related to outcomes (i.e. 
discharge placement and independence).  Individuals with decreases in IGF-1 levels during the 
first week of stroke had more desirable outcomes compared to individuals with increases in IGF-
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1 levels.  Individuals with increases in IGF-1 levels and IGF-1 ratio (defined as IGF-1:IGFBP-3) 
during the first week had a longer length of stay in the hospital, had less independence and 
greater stroke severity at one month post-stroke, and went to inpatient facilities instead of 
directly home when discharged from the hospital.  Baseline IGF-1 levels and IGF-1 ratio were 
not related to any outcomes and were not significantly different between those who went home 
or those who went to inpatient facilities. While other studies have shown that high baseline levels 
of IGF-1 are related to positive outcomes, our results may provide preliminary evidence that the 
change in IGF-1 levels and IGF-1 ratio during the first week of stroke are also important to 
recovery. Further work should be done to investigate the relationship between change in IGF-1 
levels early after stroke and functional recovery. 
In conclusion, this body of work describes physical activity and sedentary levels of 
individuals with acute stroke while they are in the hospital and how activity relates to functional 
status at discharge.  Further, discussion of using non-exercise peak VO2 in the hospital setting 
determined that predictive measures of aerobic fitness are practical and easy to use and may 
potentially have a relationship to both functional recovery and neuroprotection.  Our results 
showed that individuals with acute stroke who have higher pre-stroke fitness levels have higher 
levels of IGF-1 compared to individuals with acute stroke with lower pre-stroke fitness levels.  
Finally, this collection of studies revealed that decreases in IGF-1 levels are related to positive 
short-term outcome during stroke recovery.  This is the first investigation of how the response of 
IGF-1 during the first week post-stroke relates to outcomes and warrants future research.  The 
presented work is novel and significant in that it provides objective measures of activity and 
neuroprotection very early after stroke and new evidence for the use of easy-to-administer 
assessments of fitness.  These studies set important groundwork for additional research to 
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Every 40 seconds someone has a stroke in the United States (Go et al., 2014).  Lifetime 
risk is approximately 1 in 6 individuals, with an estimated 795,000 people experiencing new or 
recurrent strokes every year.  Nearly 610,000 of those cases are first time events and 185,000 
recurrent (Go et al., 2014).  The incidence of stroke is likely to continue to grow over the next 
decade with a projected additional 3.4 million individuals (a 20.5% increase from 2012) over the 
age of 18 years having experienced a stroke by the year 2030 (Go et al., 2014).  The prevalence 
of risk factors for stroke such as elderly age, obesity, diabetes, and heart disease is also ever-
growing (Dunstan et al., 2002; Malik, 2004; Ogden et al., 2013).  In addition, the average age of 
stroke onset has decreased, while in recent years, survival of individuals after stroke has begun to 
grow (Brown et al., 1995).  Therefore, there is a growing population of stroke survivors who are 
also living longer with their disabilities.  Stroke is among the leading causes of severe long-term 
disability in the United States (Go et al., 2014).  Many individuals  have impaired upper limb 
mobility and function such as grasping and lifting objects (Knorr et al., 2010; 
Podsiadlo,Richardson, 1991).  Additionally, they often have lower extremity weakness and loss 
of mobility that affects their ability to ambulate, especially in the community 
(Podsiadlo,Richardson, 1991).  In order to meet the need of the increased number of survivors, 
researchers and clinicians must work together to better understand recovery following stroke and 
develop novel strategies for stroke rehabilitation. 
To date, research in individuals with stroke has contributed significantly to the care these 
individuals receive during their recovery.  However, a gap still exists between the information 
gained through research and the implementation of this information during clinical practice.  In 
order to provide the most valuable information to those directly involved in patient care, studies 
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need to begin looking at this problem from a translational view-point.  One such way of 
achieving this goal is to examine both mechanistic means of neuroprotection, while also 
considering objective, clinical outcomes and interventions such as pharmaceutical administration 
or physical exercise.  Growth factors and supporting proteins, such as insulin-like growth factor-
1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) have been shown to be 
neuroprotective after stroke (Aberg et al., 2011 Bondanelli et al., 2006; De Smedt et al., 2011; 
Dempsey et al., 2003; Ebinger et al., 2015; Liu et al., 2004; Liu et al., 2001; Liu et al., 2001; 
Rizk et al., 2007; Schabitz et al., 2001; Wang et al., 2001; Zhu et al., 2008).  However, evidence 
of neuroprotection through these growth factors has primarily been shown in animal models and 
has been limited in humans by the exclusion of multiple sampling time points, the use of a large 
variability in the collection window, limited consideration of other factors that affect the 
availability of IGF-1, and the use of general questionnaires related to stroke recovery. 
In current literature, IGF-1 and IGFBP-3 are known to be influenced by modifiable 
lifestyle factors such as physical activity level, aerobic fitness, and body composition in healthy 
individuals (Chang et al., 2011 Ploughman et al., 2015; Ploughman et al., 2005 Bang et al., 1990; 
Elias et al., 2000; Scofield et al., 2011; Voss et al., 2013; Zheng et al., 2014 Carro et al., 2000; 
Rojas Vega et al., 2010 Bermon et al., 1999; Carlsen et al., 2015; Jeon,Ha, 2015).  However, 
there are no studies to test whether these relationships exist in individuals with stroke.  
Understanding the interaction between IGF-1, modifiable lifestyle factors, and recovery after 
stroke could lead to improved rehabilitation interventions and also provide benefits of improving 
health after stroke. 
In order to increase our understanding of how these growth factors might influence stroke 
recovery in humans, it is important to use a narrow sampling windows to obtain baseline 
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measures in acute stroke, and we must consider the availability of IGF-1 in circulation.  The 
current study seeks to fill the gaps and answer these important questions by implementing a 
translational approach that examines growth factors, physical activity, and stroke recovery. 
 
1.2. Physical Activity, Exercise, and Stroke 
Physical activity is important for cardiovascular health and for maintaining the ability to 
perform activities of daily living, especially among aging individuals.  Many studies around the 
world have been employed to examine the amount of physical activity individuals after stroke 
perform. 
 
1.2.1. Physical Activity and Chronic Stroke 
In community dwelling individuals post-stroke with the ability to walk independently, the 
average steps per day is 5,689 + 3,833 steps (Sakamoto et al., 2008).  Individuals in the study by 
Sakamoto and colleagues had a mean age of 63.4 (7.3) years, were on average 3.4 years from 
their stroke, and were monitored continuously for 24 hours.  Individuals in Sakamoto’s study 
spent 81% of their day either in sitting or lying positions and only 8% of their day walking.  
When these data are compared to healthy individuals over the age of 64 years, individuals post-
stroke spend less time performing physical activity, with healthy individuals spending 21% of 
their day in light activities (Arnardottir et al., 2013). 
Furthermore, one study reports as low as 1,389 steps per day in individuals post-stroke 
(Michael,Macko, 2007), while most report in the 3,000 range (English et al., 2015; Fulk et al., 
2010; Hachisuka et al., 1998; Haeuber et al., 2004; Moore et al., 2010; Roos et al., 2012).  Roos 
and colleagues directly examined the difference in walking amount and structure between 
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individuals post-stroke with no other neurological diagnoses and healthy older adults, both of 
which were community dwelling (Roos et al., 2012).  All individuals were monitored with the 
StepWatch for 3 days during waking hours, excluding time performing water activities, such as 
swimming and showering.  Healthy older adults were found to have significantly more steps per 
day, bouts per day, total time walking, and greater percent time walking.  However, steps per 
bout between groups were not significantly different.  This may suggest that the low step count 
was not limited in individuals who are post-stroke due to a lack of ability to take more steps per 
bout, but rather the number of step bouts.  Furthermore, when comparing walking structure in 
individuals who are post-stroke between groups of slow and moderate walking speeds, 
individuals post-stroke who walked slowest, had even significantly fewer steps per day, bouts 
per day, total time walking, and lower percentage of time walking, but steps per bout remained 
unchanged.  Roos suggested that the difference in walking structure between post-stroke and 
healthy individuals could be due to a lack of support from family and friends as well as 
transportation difficulties. 
English studied sitting time and its association with physical function in 40 community 
dwelling individuals post stroke and 23 age-matched, healthy controls (English et al., 2015).  
Activity was measured continuously for 7 days with both an activPAL3 and an ActiGraph 
GT3X+.  Physical function was assessed in individuals with stroke with the National Institutes of 
Health Stroke Scale (NIHSS) and Stroke Impact Scale (SIS).  People post-stroke spent 10.9 
hours per day sitting compared to the 8.2 hours the healthy controls spent sitting and sitting time 
was negatively related to physical function.  Although both healthy older adults and individuals 
after stroke were shown to spend very little time engaging in physical activity, individuals after 
stroke are at greater risk for cardiovascular decline, and engaging in increased time sitting may 
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interfere with their ability to perform activities needed for daily living.  However, this high 
amount of sedentary time may not necessarily be because they are physically incapable of 
performing activities, but rather they simply choose not to (Rand et al., 2010). 
 
1.2.2. Physical Activity and Inpatient Stroke Rehabilitation 
In the in-patient rehabilitation setting, similar patterns exist.  Observational studies were 
performed to determine the amount of time spent in therapies and other activities.  In a study by 
West and colleagues, physical activity of 130 individuals within 14 days post-stroke in an in-
patient rehabilitation setting was monitored by observations of 10 minute increments between the 
hours of 8 am and 5 pm during a single day of the work week (West et al., 2013).  They found 
that on average, individuals spent 45% of their day either out of bed or sitting supported or 
unsupported in bed and 46% of the day lying inactive in bed or performing passive activities in 
bed, such as reading or watching television.  Additionally, participants were most active when 
observed with a visitor, usually nursing staff or a family member, supporting the notion that 
family and social encouragement aid in increasing activity.  Askim studied 106 individuals with 
stroke and found that a greater amount of time spent in bed within the first 14 days of stroke was 
associated with a poorer outcome 3 months later, tested by the modified Rankin Scale (mRS) 
(Askim et al., 2014), suggesting that early mobilization may be beneficial to stroke recovery.  
However, the previously mentioned studies which examined performance of activities and bed 
sitting were performed anywhere within 14 days of stroke, have primarily been observational, 
and are short, fragmented periods of time during the day.  Valuable information regarding 
physical activity could be missed from the gaps in observation times and observation methods.  
This could potentially result in inaccuracies due to the subjective nature of observational studies.  
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Therefore, objective measures of physical activity very early after stroke are needed, but have 
not yet been performed nor examined in the United States.  The length of stay on an acute stroke 
unit is shorter in the United States.  Therefore, we need to characterize how much physical 
activity occurs during this short length of stay in the acute stroke unit.  The current collection of 
studies seeks to fill this gap in Chapter 2. 
 
1.2.3. Aerobic Fitness Measures after Stroke 
Physical inactivity can result in cardiovascular decline, which may interfere with one’s 
ability to perform activities needed for daily living.  Moreover, incorporating physical activity or 
exercise can improve overall aerobic fitness and walking endurance in people with subacute and 
chronic stroke.  However, having methods available to assess aerobic fitness across all stages of 
stroke recovery would be advantageous.  Many studies have used a metabolic cart to assess 
aerobic fitness but this method is costly, requires special equipment and trained personnel, and is 
limited by motor impairments.  Recently a submaximal exercise test was developed to predict 
aerobic fitness in healthy individuals using a recumbent stepper (Billinger et al., 2012; Herda et 
al., 2014).  This exercise device works well for people post-stroke and accommodates those with 
multiple motor impairments (Billinger et al., 2012; Billinger et al., 2008).  Furthermore, this 
exercise test does not require the expensive metabolic equipment.  Predicted peak aerobic fitness 
from the submaximal exercise test was compared to measured aerobic fitness and was found to 
be similar in people with subacute stroke (Mattlage et al., 2013).  However, evaluating aerobic 
fitness through maximal or submaximal exercise testing may not always be feasible especially 
early after stroke.  To be able to better understand whether pre-stroke aerobic fitness is related to 
stroke recovery, simpler tools to assess aerobic fitness, such as prediction equations to estimate 
peak oxygen consumption, are needed. 
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In healthy individuals, non-exercise estimations have been used to predict aerobic fitness.  
One specific non-exercise estimate equation considers factors such as: a self-reported measure of 
physical activity level, gender, age, body mass index, and resting heart rate (Jurca et al., 2005).  
Obtaining these variables would be feasible for healthcare professionals during the acute stroke 
hospital stay.  Chapter 3 uses this measure in an acute stroke population.  Information gained 
regarding this topic can be used to set the groundwork for future studies to implement exercise 
interventions, monitor cardiovascular progress to interventions, to evaluate how aerobic fitness is 
related to recovery, and how exercise can be used to harness protective benefits. 
In summary, individuals after stroke often exhibit increased sedentary behavior compared 
to their healthy counterparts.  In addition, establishing aerobic fitness levels of post-stroke 
individuals may be beneficial to understanding recovery.  However, using exercise to evaluate 
aerobic fitness soon after stroke is not always feasible due to functional limitations of motor 
impairments after stroke and limited resources for required equipment and personnel.  The use of 
non-exercise prediction equations for estimating aerobic fitness can provide a feasible and cost-
effective alternative.  In order to gain a more in-depth understanding of the benefits of aerobic 
fitness and exercise, we need to evaluate the response of potential neuroprotective factors after 
stroke that are influenced by modifiable lifestyle factors, such as aerobic fitness and physical 
activity.  Insulin-like growth fator-1 (IGF-1), a known neuroprotective agent in animal models, 







1.3. Overview of Insulin-Like Growth Factor-1 
Aside from insulin, there are two other insulin-like proteins (ILPs): insulin-like growth 
factor-1 (IGF-1), and insulin-like growth factor-2 (IGF-2).  Both of these proteins are expressed 
in high quantities during fetal and perinatal development.  After this period, both protein levels 
decrease, with IGF-2 decreasing quite substantially (LeRoith, 1997).  Therefore, IGF-2 is less 
important and plays less of a vital role during childhood, into adulthood, and old age when 
compared to IGF-1.  Although IGF-1 levels steadily decrease throughout the lifespan, this 
growth factor still remains in abundance within healthy and diseased individuals.  This single-
chain polypeptide is produced locally in the brain by nearly every cell type, but is primarily 
produced peripherally from the brain by the liver and secondarily by the pancreas.  The scope of 
IGF-1’s function is extensive, as it is involved in almost every organ of the body 
(Daughday,Rotwein, 1989).  It plays a key role in many bodily processes such as bone and 
cartilage growth, wound healing, metabolism, reproduction, angiogenesis, memory and 
cognition, neuroprotection, and neurogenesis (Hernandez et al., 1989; Mueller et al., 1991; 
Schmid et al., 1991; Spencer, 1988).  For the purposes of the current study, background 
information and study design will focus on IGF-1’s neuroprotective and neurogenerative 
potential. 
The human IGF-1 gene was discovered to have at least five exons, which code for the 
protein during transcription, and resides on the long arm of chromosome 12 (Brisenden et al., 
1984; De Pagter-Holhuizen et al., 1986; Hoppener et al., 1985; Rotwein, 1986; Tricoli et al., 
1984).  Mature IGF-1 is comprised of 70 amino acids and is encoded from the second and third 
exon on the IGF-1 gene.  There are six insulin-like growth binding proteins with IGF-1 being 
most affinitive to IGFBP-3.  When in circulation, about 95% of IGF-1 proteins are bound to 
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IGFBP-3, 4% to other IGFBPs, and 1% are found in free form (Baxter, 1994).  A ternary 
complex of 150 kilo Daltons (kDa) is formed between IGF-1, IGFBP-3, and acid-labile subunit 
(ALS).  Insulin-like binding proteins have two primary functions: 1) to regulate IGF-1 activity; 
and 2) to act as a storage facility to IGF-1.  However, most IGFBPs do have some small function 
independent of IGF-1, either inhibition or facilitation of apoptosis and cell growth.  All IGFBPs 
act as inhibitors on IGF-1 by binding with them instead of allowing them to act as a ligand to 
their receptor.  Therefore, the actions of IGF-1 are determined by the ratio of total IGF-1 to 
IGFBP-3, which can also be referred to as the availability of IGF-1.  Currently, very few studies 
have considered IGFBP-3 when investigating the response of IGF-1 blood levels after stroke in 
humans.  Because of IGFBP-3’s great influence on the availability of IGF-1, it is extremely 
important to quantify IGFBP-3 alongside the quantification of IGF-1.  Without this information, 
the ability to draw meaningful conclusions about the response of IGF-1 in individuals with stroke 
is extremely limited.  The current study seeks to fill this gap by quantifying both proteins. 
 
1.3.1. Insulin-Like Growth Factor-1 Signaling, Pathways, and Action 
As mentioned previously, IGF-1 is produced both locally in the brain by cells containing 
IGF-1 messenger ribonucleic acid (mRNA) and also peripherally from the brain by the liver.  
Because IGF-1 is synthesized from these two locations, it exhibits both endocrine and paracrine 




Figure 1.1. Endocrine/Paracrine Signaling of Neuroprotection 
 
Figure used with permission from Iadecola et al. in Nature Neuroscience, 2011 
 
After injury, there is a protective cell-to-cell communication within the brain between 
neurons, astrocytes, microglia, and blood vessels through a response to excessive glutamate and 
growth factor release.  This system is involved in homeostasis of the tissues within the brain by 
sustaining cerebral blood flow, decreasing excitotoxicity, preventing inflammation and 
apoptosis, and promoting mechanisms of repair.  Signaling from the brain supports both central 
processes and peripheral organs such as the cardiovascular system, while peripheral signaling 
feeds back to the brain to provide neuroprotection and repair.  Although almost every cell type in 
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the mammalian brain contains IGF-1 mRNA, both endocrine and paracrine signaling play 
significant roles in cell growth and protection after cerebral injury.  It has been shown that in the 
brain there is a low level of IGF-1, but a high level of IGF-1 receptors (Carro et al., 2000; Trejo 
et al., 2001), suggesting that additional IGF-1 from the periphery is needed for neuroprotection 
in the brain.  The receptor for IGF-1 (IGF-1R) is a transmembrane, tyrosine-kinase receptor.  In 
the adult mouse, IGF-1Rs are widely distributed and expressed in most abundance in the 
neocortex, thalamus, and choroid plexus (see Figure 1.2).  The distribution of IGF-1Rs is similar 
in the adult human brain (Adem et al., 1989; De Keyser et al., 1994). 
 
Figure 1.2. Distribution of IGF-1R in Mice 
 
Figure used with permission from Fernandez et al. in Nature Reviews Neuroscience, 2012 




In humans brains, epithelial cells in the choroid plexus and endothelial cells in brain 
vessels have the highest distribution of IGF-1 receptors (Bondy,Lee, 1993).  Peripherally 
synthesized IGF-1 can enter the brain from circulation via two routes: 1) through the choroid 
plexus (CP) to the cerebral spinal fluid (CSF) and finally to brain parenchyma (Figure 1.3); or 2) 
directly from circulation through the blood brain barrier (BBB) (Figure 1.4), further supporting 
the idea that paracrine signaling from circulating IGF-1 plays an important role centrally in the 
brain. 
 
Figure 1.3. IGF-1 from CP-CSF-Parenchyma       Figure 1.4. IGF-1 from BBB Parenchyma 
   
 
Figures used with permission from Fernandez et al. in Nature Reviews Neuroscience, 2012 
 
The CP is a network of capillaries within the ventricles of the brain with a primary 
function of producing CSF.  Fluid from the blood is filtered through epithelial cells of the CP to 
eventually become CSF.  Amount of IGF-1 entrance into the brain through this process is 
directly related to the level in circulation.  Figure 1.3 depicts transcytosis of IGF-1 from the CP 
to its receptor in the CSF and eventually on to the brain parenchyma with the help of low-density 
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lipoprotein receptor-related protein 2 (LRP2).  Insulin-like growth factor-1 that interacts with the 
brain through the CP typically supplies areas closest to the ventricles such as the hypothalamus 
and the hippocampus.  Areas that are geographically farther away from the CP are less accessible 
for IGF-1 and must use and rely primarily on either a transportation system or locally 
synthesized IGF-1.  Figure 1.4 represents the process of IGF-1 entering the brain parenchyma 
through IGF-1 receptors in endothelial cells in the BBB with the help of LRP1.  Injury and the 
activation of neuronal cells results in glutamate release, which enhances local blood flow.  With 
an enhancement in blood flow, the levels of the ternary complex of IGF-1, IGFBP-3 and ALS is 
also increased (Chiu et al., 2008; Scolnick et al., 2008).  However, in order for IGF-1 to reach its 
receptor, IGF-1 must be disassociated from its bound proteins.  Several mediators such as 
prostaglandin E2 (PGE2) and adenosine triphosphate (ATP) are also released during this 
processes that stimulates matrix metalloproteinase 9 (MMP9).  One important function of MMP9 
is to aid in the disassociation of IGF-1 from IGFBP-3, allowing it to attach to its receptor in the 
endothelium.  Once attached to its endothelial receptor, LRP1 helps IGF-1 to be picked up by the 
glial end-feet of astrocytes and then is transferred to the IGF-1R of a neuron for activation of its 
function.  Figure 1.5 demonstrates this process. 
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Figure 1.5. BBB IGF-1 Attachment to Astrocyte and Neuron 
 
Figure used with permission from Fernandez et al. in Nature Reviews Neuroscience, 2012 
 
In the event of a cerebral injury, locally produced IGF-1 and IGF-1 from circulation 
target activated neurons.  An experimental study showed evidence of this by inducing a middle 
cerebral artery occlusion (MCAO) in rats and administering IGF-1 immediately after.  Within 30 
minutes of IGF-1 administration, the majority of IGF-1 proteins were associated with neurons of 
the infarcted (activated) hemisphere (Guan et al., 1996). 
As mentioned previously, IGF-1 has a transmembrane, tyrosine-kinase cell surface 
receptor, IGF-1R.  This class of receptors is made up of single subunits that dimerize when a 
ligand, such as IGF-1, is attached.  Each subunit has two terminals, an extracellular N-terminal 
(amino-terminal) and an intracellular C-terminal (carboxyl-terminal).  The extracellular N-
terminal is the binding site for the ligands, while the intracellular C-terminal houses the tyrosines 
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and is also responsible for the kinase, or phosphorylation, activity of the receptor.  When IGF-1 
attaches to the N-terminal of its receptor, several signaling cascades occur within two major 
pathways: the Ras/mitogen-activated protein kinases (MAPK) pathway (Ras/MAPK) and the 
phosphatidylinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway (PI3K/Akt).  Each 
pathway and signaling cascade is responsible for a different action (Figure 1.6).  The 
Ras/MAPK pathway activates cell proliferation, while the PI3K/Akt pathway has three 
functions: 1) inhibition of apoptosis; 2) protein synthesis; and 3) prevention of inhibition of 
proliferation (or facilitation of cellular proliferation). 
The signaling cascade of the Ras/MAPK pathway is initiated by IGF-1 acting as a ligand 
and binding to its receptor.  Two subunits of the tyrosine kinase receptor dimerize and the 
tyrosines on both C-terminals are phosphorylated, allowing growth factor receptor-bound protein 
2 (GRB2) to bind to the phosphorylated receptor.  Son of Sevenless (SOS) then binds to both 
GRB2 and Ras, a membrane bound protein.  When Ras is inactivated, it is bound to the 
nucleotide guanosine diphosphate (GDP).  In order for Ras to activate, SOS must catalyze the 
replacement of GDP with guanosine triphosphate (GTP) attached to Ras.  Now the activated Ras, 
attached to GTP and disassociated with SOS, is able to bind to B-Raf.  The kinase B-Raf 
activates MEK 1 and 2 by phosphorylating them, which in turn phosphorylates extracellular 
signal-regulated kinase (ERK) 1 and 2.  This cascade leads the activation of transcription factors 
in the activator protein 1 (AP-1) family.  Two of the primary transcription factors in this family 
are fos and jun.  Jun and fos move to the nucleus and attach AP-1 expression on the DNA.  
Finally, this activates cellular proliferation through Ras at the cell membrane. 
Signaling of the PI3K/Akt pathway is also initiated in the same manner as the 
Ras/MAPK pathway by IGF-1 binding to IGF-1R at the cell surface.  Again, tyrosines on the C-
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terminal are phosphorylated which allows insulin-receptor substrate-1 (IRS-1) to bind to the 
phosphorylated receptor and PI3K to bind to IRS-1.  Phosphorylated PI3K then disassociates 
with IRS-1 and binds to membrane-bound phosphatidylinositol 4,5-biphosphate (PIP2).  Next, 
PIP2 is phosphorylated and becomes phosphatidylinositol 3,4,5-triphosphate (PIP3), which 
activates Akt.  From here, Akt goes on to follow three different signaling pathways, each with a 
different function.  First, Akt can inhibit apoptosis, or programed cell death, by binding to B-cell 
lymphoma 2 (BCL2)-associate X protein (BAX).  When not bound to Akt, BAX initiates 
apoptosis by forming holes in the outer mitochondrial membrane.  Second, Akt initiates protein 
synthesis, or translation, through the Akt/mTOR signaling pathway.  After Akt is activated by 
PIP3, it phosphorylates Ras homolog enriched in brain (RHEB), which activates mammalian 
target of rapamycin (mTOR).  Then, mTOR activates the translation factor S6 kinase (S6K).  
Finally, S6K binds to ribosomes to activate protein synthesis.  The third signaling pathway of 
Akt facilitates cellular proliferation by decreasing the concentration of forkhead box O (FOXO), 
which inhibits proliferation.  After Akt is activated, it “tags” FOXO to be destroyed by 
phosphorylating it.  Once FOXO is phosphorylated, ubiquitin ligase recognizes it and transfers 
ubiquitin peptides onto FOXO.  Ubiquitinated FOXO is then destroyed by proteasomes. 
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Figure 1.6. IGF-1 Signaling Pathways 
 
Figure created as part of the current dissertation 
 
Many factors regulate the amount of IGF-1 that is released into blood circulation as well 
as the level of IGF-1 mRNA. Growth hormone produced from the pituitary is well established as 
mediator of IGF-1 synthesis.  Circulating growth hormone interacts with hepatic receptors and 
results in stimulation of IGF-1 production and secretion (Johnson et al., 1989; Mathews et al., 
1986), which interacts with the whole body as opposed to specific areas or organs.  Growth 
hormone also regulates IGF-1 mRNA expression in the brain.  In a mouse model, Mathews and 
colleagues showed that IGF-1 mRNA in the brain was altered due to growth hormone deficiency 
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(Mathews et al., 1986).  Other hormones have a more target specific effect on the abundance of 
IGF-1 mRNA.  For example, estrogen is a prime regulator in the female reproduction system by 
stimulating IGF-1 mRNA in the uterus as well as ovarian granulosa cells (Murphy et al., 1987).  
Another example of this concept is parathyroid hormone, which regulates bone growth by 
increasing IGF-1 peptide production (McCarthy et al., 1989).  Finally, in culture, glucocorticoid 
dexamethasone, a steroidal hormone that decreases inflammation activity, also decreased IGF-1 
mRNA in neuronal and glial cells (Adamo et al., 1988).  However, how this translates to clinical 
populations is still unclear. 
 
1.3.2. IGF-1 Regulation 
Nutrition and exercise also have been shown to regulate IGF-1 levels.  Elmer and Schalch 
were the first to observe decreases in IGF-1 mRNA in the rat liver after fasting (Emler,Schlach, 
1987).  These levels were restored after fasting ended.  This concept was supported after Lowe et 
al observed the same thing (Lowe et al., 1989).  In the clinical model, fasting caused a decrease 
in IGF-1 within 24 hours (Clemmons et al., 1981).  On day ten of fasting, IGF-1 levels were 20% 
of pre-fasting levels.  Several studies have also been conducted examining the effect of exercise 
on IGF-1 levels.  A study performed by Cappon et al, aimed at determining the effect of exercise 
on IGF-1 levels as well as how differences in diet will effect these levels (Cappon et al., 1994).  
Ten healthy participants between the ages of 22-35 years exercised above their lactate threshold 
on a cycle ergometer on three separate mornings for 10 minutes each.  Each morning they were 
either given a high-fat, high-glucose, or placebo meal.  Blood was sampled 10 minutes prior to 
exercise, immediately prior to exercise, and every 10 minutes for 90 minutes after the start of 
exercise.  They observed that IGF-1 significantly increased with exercise, peaking at 10 minutes 
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after the start of exercise.  However, they found that the type of meal ingested before exercise 
had no effect on IGF-1 levels at any time point.  Schwarz et al later examined the relationship 
between aerobic exercise and acute changes in IGF-1 levels using two different intensities (high- 
and low-intensity) (Schwarz et al., 1996).  This study supported Cappon et al.’s results.  Ten 
healthy males who were regular exercisers underwent three separate conditions:  resting quietly, 
10 minutes of low-intensity exercise, and 10 minutes of high-intensity exercise, and high-
intensity exercise.  Blood was sampled 5 minutes prior to the onset of exercise, immediately 
upon onset of exercise, 5 minutes into exercise, immediately upon cessation of exercise, and 
every 10 minutes after exercise for an hour.  Blood was sampled following the same time 
increments during the resting condition.  Blood levels of IGF-1 and IGFBP-3 peaked after 10 
minutes of exercise and did so on a dose-dependent basis.  High-intensity exercise showed 
significantly elevated levels of IGF-1 and IGFBP-3 compared to low-intensity exercise and rest.  
Further, low-intensity excise elicited significant increases in blood levels compared to rest 
(Schwarz et al., 1996).  The results of Schwarz et al. and Cappon et al. studies are important to 
stroke and neurological recovery because if evidence continues to be uncovered in support of 
IGF-1 as a neuronal rescue agent after injury, it is possible that exercise can be used as an 
intervention technique to utilize and enhance IGF-1’s benefits during recovery.   
However, not all studies demonstrate an increase in IGF-1 levels following exercise.  
Suikkari and colleagues had participants complete a three hour cycle ergometer exercise 
(Suikkari et al., 1989).  No increases in IGF-1 were observed after completion, but significant 
increases in IGFBP-3 were observed. 
The observed differences in results from the Cappon and Schwarz studies to the Suikkari 
study could have been attributed by many factors.  Intensity, duration, and mode of exercise 
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needs to be considered as well as time of sampling in relation to exercise onset.  As evident by 
Schwarz study, there seems to be a dosing affect in the magnitude of IGF-1 elevation due to 
different intensities of exercise.  Mode of exercise (i.e. running, cycling, resistance training) may 
also have an influence on the magnitude of elevation in IGF-1.  Differences in results could also 
be due to time of sample in relation to exercise onset and completion.  If IGF-1 is not sampled 
frequently enough or at the right time, peak levels could be missed and interpreted incorrectly.  
Additional studies need to be performed to evaluate the influence of these factors on IGF-1 and 
IGFBP-3 blood levels, but are not within the scope of the current studies. 
Other factors such as age, body mass index (BMI), and gender have been shown to have an 
effect on circulating IGF-1 levels in the clinical population.  Circulating IGF-1 levels steadily 
decrease across the lifespan (Friedrich et al., 2008; Friedrich et al., 2010; Guven et al., 2013; 
Kehinde et al., 2005; Mattsson et al., 2008; Morimoto et al., 2005).  Higher BMI has been 
associated with lower circulating IGF-1 (Morimoto et al., 2005).  Finally, females typically have 
higher IGF-1 levels when compared to males (Friedrich et al., 2008; Friedrich et al., 2010; 
Morimoto et al., 2005).  There have been numerous studies performed to determine reference 
ranges of IGF-1 in healthy individuals (Friedrich et al., 2008; Friedrich et al., 2010; Guven et al., 
2013; Kehinde et al., 2005; Mattsson et al., 2008; Morimoto et al., 2005).  
Previous studies have shown that IGF-1 follows a circadian pattern in healthy individuals 
and those with cancer.  Mazzoccoli and colleagues quantified IGF-1 levels over 24 hours in men 
with lung cancer and healthy men (Mazzoccoli et al., 2012).  Blood was sampled every six hours.  
They found that MESOR values, or the arithmetic mean, was significantly higher in healthy men 
compared to men with cancer.  The amplitude of healthy individuals was also significantly 
larger.  Finally, the peak value in healthy individuals occurred later in the morning compared to 
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men with cancer.  Haus also quantified IGF-1 and IGFBP-3 levels over a 24 hour period in 
women with breast cancer Haus et al., 2001.  They found that women with breast cancer also 
follow a circadian rhythm of IGF-1 and IGFBP-3.  However, no studies have determined IGF-1 
circadian patterns in neurological injury such as stroke.  This proposed study seeks to fill this gap 
in the literature.  This information will give us a more comprehensive look to response of IGF-1 
after stroke and how it relates to outcomes after stroke. 
 
1.3.3. Quantification of IGF-1 Blood Levels through Enzyme-Linked Immunosorbent assay 
(ELISA) Analysis 
Radioimmunoassay (RIA) is considered a gold-standard method of quantifying the 
concentration of an antigen of interest in serum or plasma with the use of antibodies.  The 
antigen of interest is typically labeled, or “tagged”, with a radioactive iodine isotope.  An 
antibody for that antigen is then mixed in, resulting in a complex of the radioactive antigen and 
the antibody.  During the experiment known concentrations are used to determine the 
concentration in the unknown serum/plasma samples.  A gamma-counter is then used to measure 
the radioactivity of each sample and the concentration of the antigen of each sample can then be 
derived.  However, this method has since been replaced with a newer method, enzyme-linked 
immunosorbent assay (ELISA).  Analysis of antigens using ELISA is typically favored over RIA 
for several reasons.  First, RIA requires special precautions due to the use of radioactive 
materials. Contrarily, ELISA eliminates the use of radioactive substances and therefore requires 
fewer precautions.  Instead, ELISA analysis uses colorimetric measurements including light 
absorbance or fluorescence.  Analysis by RIA also generally takes several days to complete, 
whereas ELISAs can be completed in a single day.  Finally, both of these methods result in 
similar sensitivity of measurements. 
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When using ELISA analysis to determine the availability of IGF-1 to reach its receptor, 
there are several factors one must consider.  First, as mentioned previously, IGF-1 is most 
abundantly found in a ternary complex with IGFBP-3 and ALS.  In order to determine total 
amount of circulating IGF-1, it must first be disassociated from its ternary complex.  To do this, 
acidic buffer is added to strip IGF-1 from the complex.  The acidic samples are then neutralized 
and an antibody for IGF-1 is added.  Then IGF-1 disassociates from IGFBP-3 and IGF-2 takes its 
place.  Cross-reactivity of the IGF-1 antibody with IGF-2 is extremely low.  Thus, the ELISA kit 
is incredibly specific to IGF-1 and measured concentrations are accurate.  After determining total 
concentration of circulating IGF-1, one must also consider the amount of IGFBP-3 to measure 
the true availability of IGF-1 to reach its receptor.  To do this, IGFBP-3 levels can be assayed 
using ELISA as well. 
 
1.4. Stroke and IGF-1 Levels in the Experimental Animal Model 
There are two phases of an ischemic stroke, a primary phase and a secondary phase.  The 
primary phase occurs immediately during the insult.  A secondary phase occurs hours later in 
which there is a delayed cell loss, making up the penumbra (Beilharz et al., 1995; Lorek et al., 
1994; Williams et al., 1991; WIlliams et al., 1992).  Stroke research has focused on prevention of 
the secondary loss of neuronal cells.  As mentioned earlier, a cascade of events due to  IGF-1 
attaching to it’s receptor result in neuroprotection through stimulation of cellular proliferation 
and protein synthesis and inhibition of apoptosis.  Experimental models have extensively 
demonstrated the potential of IGF-1 to act as a neuronal rescue agent after stroke.  IGF-1 level 
was increased after injury in proportion to the degree of insult and associated with cells where 
neuronal death occurred in the injured hemisphere (Beilharz et al., 1998).  Further, previous 
studies have shown that administration of IGF-1 after cerebral insult may be beneficial by 
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delaying or reducing secondary neuronal loss (Guan et al., 1996; Johnston et al., 1996; Schabitz 
et al., 2001).  Evidence suggests that a single dose of IGF-1 can reduce cortical lesion size from 
94% in placebo rats to 24% in experimental rats (Guan et al., 1993).  Guan et al demonstrated 
that there is a dose dependent response of administration of IGF-1 in reduction of neuronal loss 
in all areas of the brain, such that increased amounts of administered IGF-1 will lead to increases 
in positive outcomes (Guan et al., 1993).  In rats, administration of 75 µg IGF-1 through 
intranasal delivery 10 minutes, 24 hours, and 48 hours after the onset of MCAO also showed 
reduced infarct volume by 60%  and hemispheric swelling by 45.6% compared to vehicle 
controls (Liu et al., 2001).  This same study also assessed neurological function through reflex 
response and demonstrated improvements compared to vehicle controls.  Neurological functional 
assessments included motor-sensory (postural reflexes and flexor responses) and somatosensory 
(adhesive tape) tests.  Rats who were treated with IGF-1 showed significantly lower deficits in 
all functional assessments compared to vehicle control rats up to 75 hours following MCAO.  
Results of these studies indicate that using IGF-1 as a pharmaceutical rescue agent or finding 
ways to up-regulate IGF-1 beginning early after stroke may decrease lesion size of the injured 
hemisphere and contribute significantly to functional status during recovery. 
Experimental models have also shown that exercise and IGF-1 may work together to 
mediate these neuroprotective effects on the brain.  Chang and colleagues demonstrated this by 
assigning rats to one of four groups [MCAO with and without exercise training as well as 
MCAO with IGF-1 receptor inhibition with and without exercise training] (Chang et al., 2011).  
They observed that MCAO rats who participated in exercise had significantly higher levels of 
IGF-1 in the affected motor cortex when compared to the MCAO rats who did not exercise, 
indicating that exercise may facilitate IGF-1 entrance into the brain.  Further, exercising MCAO 
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rats showed decreases in lesion size as well as improved motor function.  Daily injection of IGF-
1 receptor inhibitors mitigated all of these effects, further indicating that IGF-1 may mediate 
beneficial effects of exercise (Chang et al., 2011).  Interestingly, Zheng and colleagues found 
strong evidence that IGF-1 signaling is a likely mechanism of functional neurological 
improvement in rats as a result of an exercise intervention after experimental stroke (Zheng et 
al., 2014).  Zheng performed MCAOs on 40 male rats.  One group of rats was used as controls, 
with only a stationary wheel in their cages, while another group was subjected to an exercise 
intervention that consisted of running for 20 minutes, twice daily, for three days post-ischemia.  
Neurological function of rats was evaluated using the modified Neurological Severity Scores 
(mNSS) scale on day 3, 7, and 14 following MCAO.  Rats who underwent the exercise 
intervention scored significantly better on the mNSS on days 7 and even more so on day 14.  
However, on day 3 following MCAO, both groups showed no difference in neurological 
function, suggesting that there may be a latency period between an exercise intervention and 
functional neurological improvements. 
Further, this same pattern was observed in infarct lesion volumes, with day 3 showing no 
significant difference and days 7 and 14 showing increasingly greater significant differences 
between exercisers and sedentary, with exercisers exhibiting significantly  smaller lesion 
volumes.  Even more, Zheng and co-workers showed evidence to suggest that IGF-1 signaling 
may be a mechanism behind these observed improvements through the sprouting of newborn 
neurons and decreases in apoptosis of cells in the infarcted hemisphere (Zheng et al., 2014).  
Immuno-staining and western-blots showed increases in neural progenitor cells, Nestin and 
NeuN.  Further, exercise activated IGF-1 signaling through the Akt pathway with the expression 
of IGF-1 and p-Akt drastically increased after exercise.  Notably, the same pattern exists once 
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again with the increases in progenitor cells and expression of IGF-1 and Akt not occurring until 
days 7 and 14.  It is clear that Zheng provides compelling evidence to suggest that exercise after 
stroke can lead to increases in IGF-1 through the Akt pathway, providing necessary 
neuroprotection to improve functional recovery in rats.  While exercise and IGF-1 look very 
promising in the animal model, it is still unclear whether these benefits exist in a clinical 
population. 
 
1.5. IGF-1 in the Clinical Population 
Encouraging results of IGF-1 neuroprotection have been extensively shown in animal 
models of stroke.  However, the ability for these concepts to translate over to clinical models is 
still unclear.  Several studies have been performed in the clinical population, however, the 
application of these studies to interpret IGF-1 response after stroke is limited.  Available 
evidence shows that individuals with low IGF-1 levels have a greater risk of ischemic heart 
disease, myocardial infarction, coronary artery disease, and a lower incidence of diabetes (Juul, 
2002; Laughlin, 2004; Okura, 2001; Vasan et al., 2003).  All these conditions are risk factors for 
stroke.  Further, bottom quartile levels of IGF-1 have been directly associated with stroke risk in 
humans (Bondanelli et al., 2006; Denti et al., 2004; Johnsen, 2005; Tang et al., 2014).  Very few 
studies have been conducted examining IGF-1 levels after clinical stroke and whether this is 
related to functional recovery and/or lesion size.  Denti and colleagues examined IGF-1 and 
IGFBP-3 levels in 85 acute stroke participants and 88 healthy controls (Denti et al., 2004).  At 
baseline, stroke participants had significantly lower IGF-1 levels compared to healthy controls.  
Stroke severity by the Barthel Index (BI) was assessed at 3 months and 6 months post-stroke.  
Low IGF-1 levels early after stroke were associated with a higher stroke severity as well as lower 
survival rate at 3 months and 6 months post-stroke. 
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DeSmedt further demonstrated the relationship between IGF-1 levels and stroke 
outcomes by examining IGF-1 and IGFBP-3 levels very early after stroke and stroke severity by 
the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) (De 
Smedt et al., 2011).  The results of this study showed that even when controlling for risk factors 
(i.e hypertension, diabetes, atrial fibrillation, coronary artery disease, heart failure, smoking, and 
previous stroke), lower than median IGF-1 levels were related to increased stroke severity and 
lower survival rates at 3 and 6 months post-stroke when compared to those with high IGF-1.  
Baseline stroke severity was not significantly different between low and high IGF-1 individuals, 
indicating that IGF-1 may not be influenced by the original severity of stroke.  Aberg and 
colleagues studied 407 acute stroke patients and also found individuals with higher than median 
IGF-1 had improved outcomes 3 and 24 months post-stroke demonstrated by the Scandinavian 
Stroke Scale (SSS) and mRS (Aberg et al., 2011).  Aberg observed that IGF-1 levels were 
elevated in the acute stage of stroke when compared to healthy controls.  The conflicting 
evidence in baseline IGF-1 levels in individuals with acute stroke and healthy controls between 
the study by Denti and the study by Aberg, could be attributed to factors such as age of the 
compared groups, sampling time of IGF-1 in relation to stroke onset, and variation in sampling 
time of day.  Nonetheless, the results of these studies are encouraging evidence to show that IGF-
1 may be an important biomarker for neuroprotection after stroke. 
 
1.6. Significance of the Presented Work 
This dissertation work is novel and significant as it is a translational project examining 
physical activity levels, estimated aerobic fitness, and the response of IGF-1, IGFBP-3, and IGF-
1 ratio and their relationship to outcomes after stroke in humans.  To our knowledge, this is the 
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first collection of studies in acute stroke to closely examine the ratio of IGF-1 to IGFBP-3, or the 
availability, across tightly controlled multiple time-points and how it relates to physical activity, 
estimated aerobic fitness, and clinical outcomes following stroke.  This study bridges the gap 
between current knowledge of the neuroprotective qualities of IGF-1 seen in animals models of 
stroke, the interaction between physical activity and IGF-1 in healthy humans, and the response 
of IGF-1 during clinical stroke recovery. 
Chapter 2 examines sedentary time on the acute stroke unit using an objective measure, 
accelerometry.  This was the first study conducted in the United States using accelerometry on 
the acute stroke unit.  Current literature has described physical activity during most phases of 
stroke recovery.  Unfortunately, most of this work has been done in the later phases of recovery.  
The several studies which sought to gain information during the acute and early sub-acute phases 
have been limited in that they used subjective, observational methodology only.  Chapter 2 
improves upon this information by providing objective measures of activity using 24-hour 
monitoring actigraphy for several days after admission to the hospital with acute stroke.  The 
results of this study showed that individuals in the acute hospital setting spend very little time 
performing activities with an intensity of “light” and above, while they spend most of their time 
engaging in sedentary behavior.  Further, the amount of time spent sedentary was significantly 
correlated with function at discharge from the hospital, regardless of function upon admission.  
These important results add to this collection of work by providing a foundation on which to 
provide beginning evidence that physical activity may provide benefit early after stroke.  
However, the response of IGF-1 after stroke and how it is related to recovery has still yet to be 
determined and is sought after through the following chapters.  It was the goal of this dissertation 
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work to provide insight into this important issue and provide groundwork to guide rehabilitation 
techniques in the future. 
From Chapter 2, we learn that physical activity during the acute stroke hospital stay may 
have a role in improving function.  However, it is not always possible or feasible to collect 
objective measurements of aerobic fitness and physical activity due to limitations in motor 
impairments and resources, such as cost or time.  In Chapter 3, discussion is focused on the use 
and feasibility of measurement tools to estimate aerobic fitness at the time of stroke admission.  
The use of this tool will become very useful in later chapters in order to provide knowledge to 
the field regarding the relationship between estimated aerobic fitness and the change in IGF-1 
levels and the availability of IGF-1 during the first week of stroke. 
Chapters 4 and 5 seek to outline possible growth factors after stroke that may related to 
recovery, physical activity, and exercise.  It is in these chapters that we have formulated our 
aims.  First, this project seeks to fill the aforementioned gaps in the literature by providing 
information on the availability of IGF-1 in individuals with acute stroke and how it relates to 
estimated aerobic fitness (Aim 1).  Previous research suggests that levels of IGF-1 is influenced 
by both physical activity levels and aerobic fitness.  Additionally, research shows that physical 
activity after stroke can lead to improved outcomes and decreases in stroke severity.  However, 
no work has been done to understand the intersection of these two early after stroke.  If the 
scientific questions proposed in this study are supported, it will provide evidence to suggest that 
IGF-1 is an important growth factor related to stroke recovery and may be able to be positively 
influenced by interventions, such as physical activity.  We can use the information gathered from 
this proposed study to guide future studies and also perhaps assist clinicians in the design of 
future of rehabilitation protocols.  This study has the potential to provide a strong foundation 
30 
 
needed for future studies to focus on understanding ways to up regulate IGF-1 for maximizing 
neuroprotection.  
Second, we will address the complex and conflicting information available to determine 
the relationship of the response of IGF-1, IGFBP-3, and IGF-1 availability during the first week 
of stroke to days spent in the hospital, functional independence at one-month post-stroke, and 
discharge destination (i.e. individuals who discharge home vs. individuals who discharge to 
inpatient facilities) (Aim 2 and 3).  Knowledge exists regarding the relationship between IGF-1 
and stroke severity, however, these studies did not examine IGFBP-3 levels, nor the availability 
of IGF-1, an important factor to consider when studying stroke recovery.  Further, there is no 
information regarding hospital length of stay, functional independence at one-month post stroke, 
and discharge destination and their relationship to IGF-1 in individuals with acute stroke.  This 
information may be beneficial in order to predict outcomes and implement appropriate early 
interventions to those who are most at risk for sustained impairments due to stroke. 
 
1.7. Summary 
Insulin-like growth factor-1 has been shown to be neuroprotective after cerebral injury 
and plays a key role in inhibition of apoptosis in people and animals.  Experimental models of 
stroke have shown that IGF-1 is necessary for recovery and may act as a neuronal rescue agent.  
Animals that were injected with IGF-1 after insult showed smaller lesion sizes and better 
functional recovery than those with vehicle control only.  Although, these results seem 
promising, it is still unknown if this concept is translational to humans.  Few studies have been 
performed examining IGF-1 levels and its relationship to diseased states such as stroke.  In the 
clinical model, studies have shown that above median IGF-1 levels can lead to better scores on 
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the NIHSS and mRS and even higher survival rates at three months post-stroke (Aberg et al., 
2011; De Smedt et al., 2011; Denti et al., 2004).  However, these two scales are global 
questionnaires assessing severity of stroke symptoms, neurological deficit, and independence in 
activities of daily living, which may not be complete measures of stroke recovery.  Therefore, 
this proposed study aims to add to this current knowledge by providing measures of stroke 
recovery and improved measures of IGF-1 blood levels.  This may be important in guiding 
clinical rehabilitation in future by providing further evidence of IGF-1’s potential for 
neuroprotection and lay a groundwork for future studies in order to examine methods of 
facilitating IGF-1 uptake into the brain and other injured regions. 
 
1.8. Specific Aims and Statement of Hypotheses 
Insulin-like growth factor 1 (IGF-1) is an important biomarker of neurogenesis and 
inhibition of apoptosis. Effort has been expended on determining the role of IGF-1 in neuronal 
recovery and in inhibiting neuronal apoptosis after brain injury. In animal models, IGF-1 appears 
to be an important factor in providing neuroprotection after cerebral insult by delaying and/or 
inhibiting apoptosis of brain neuronal cells (Kulik et al., 1997).  It has been demonstrated that 
intranasal administration of IGF-1 to rats reduces infarct volume 60 – 63% and significantly 
improves assessments of motor, sensory, and reflex function following middle cerebral artery 
occlusion as compared to control animals (Guan et al., 1996; Johnston et al., 1996; Liu et al., 
2001; Liu et al., 2001; Schabitz et al., 2001).  Facilitation of IGF-1 is largely modulated by IGF 
binding protein-3 (IGFBP-3) (Baxter, 1994).  Attachment of IGF-1 to IGFBP-3 decreases the 
availability of the hormone to attach to its receptor.  Therefore, it is important to consider the 
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level of IGFP-3 and the availability of IGF-1 when studying the potential effectiveness of the 
hormone in vivo. 
However, our understanding of the neuroprotective effect and regulation of IGF-1 after 
stroke in the clinical population is very limited.  Previous studies in humans have shown that 
individuals after stroke who have above median levels of circulating IGF-1 have higher scores on 
the National Institutes of Health Stroke Scale and a higher survival rate at 3 months post-stroke 
than those with lower circulating levels (Aberg et al., 2011; De Smedt et al., 2011).  IGF-1 is 
produced both locally in the brain and peripherally in the liver by cells with IGF-1 gene 
expression.  It has been shown that in the brain there is a low level of IGF-1, but a high level of 
IGF-1 receptors (Carro et al., 2000; Trejo et al., 2001), suggesting that additional IGF-1 from the 
periphery is needed for neuroprotection in the brain.  A more complete understanding of the 
regulation and availability of IGF-1 after stroke and the relationship between this hormone and 
stroke recovery could yield new approaches for overcoming or preventing the stroke-induced 
neurological damage that is responsible for the long-term disability.  The results of the proposed 
study have the potential to set the groundwork for further studies by providing critical 
information about important neuroprotective biomarkers after stroke. The goal of the study was 
to determine the relationship between IGF-1 response, estimated aerobic fitness, and stroke 
outcomes following an acute stroke in humans.  To our knowledge, no studies have examined 
the IGF-1 blood level response, combined with the availability of IGF-1 during acute stroke.  
Therefore, to measure blood levels of IGF-1 and IGFBP-3, blood samples were collected within 
72 hours of admission to the hospital for acute stroke and at one week post-stroke.  Physical 
activity levels prior to the stroke, estimated aerobic fitness at the time of stroke, and outcomes of 
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stroke recovery were also collected through questionnaires and electronic medical records.  We 
tested our overall hypothesis with the following three specific aims: 
 
Specific Aim 1:  Determine the relationship of IGF-1 and IGFBP-3 to estimated aerobic 
fitness (peak VO2) in individuals with acute stroke. 
We hypothesize that estimated pre-stroke peak VO2 would be significantly and positively related 
to IGF-1 and inversely related to IGFBP-3 (H1a).  Additionally, we hypothesized that 
individuals with higher than median circulating IGF-1 levels would have significantly higher 
estimated pre-stroke peak VO2 compared to those with lower than median levels (H1b) 
 
Specific Aim 2:  Determine the relationship between percent change in IGF-1 and IGF-1 
ratio during the first week of stroke and stroke outcomes (i.e. LOS and mRS at one-month 
post-stroke). 
We hypothesize that an increase in IGF-1 and IGF-1 ratio during the first week of stroke would 
be associated with fewer days spend in the hospital (LOS) and more functional independence at 
one-month post-stroke (mRS) (H2). 
 
Specific Aim 3:  Determine the difference in percent change in IGF-1 and IGF-1 ratio in 
discharge destination (i.e. individuals who discharged home vs. individuals who discharged 
to inpatient facilities. 
We hypothesized that individuals who discharged home will have significantly greater percent 
change in IGF-1 and IGF-1 ratio compared to individuals who discharge to inpatient facilities. 
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2. CHAPTER 2. USE OF ACCELEROMETERS TO 
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Background and Purpose: Observational studies demonstrate low levels of physical activity 
during in-patient stroke rehabilitation.  There is no objective measure of sedentary time on the 
acute stroke unit and whether sedentary time is related to functional outcomes.  The purpose of 
this study was to characterize sedentary time after acute stroke and determine whether there is a 
relationship to functional performance at discharge.  Methods:  Thirty-two individuals (18 
males; 56.5 + 12.7 years) with acute stroke were enrolled within 48 hours of hospital admission.  
An accelerometer was placed on the stroke-affected ankle to measure 24-hour activity and was 
worn for 4 days or until discharge from the hospital.  Performance of activities of daily living, 
walking endurance, and functional mobility was assessed using the Physical Performance Test 
(PPT), Six-Minute Walk Test (6MWT), and Timed-Up and Go (TUG), respectively.  Results:  
Mean percent time spent sedentary was 93.9 + 4.1% and percent time in light activity was 5.1 + 
2.4%.  When controlling for baseline performance, the mean time spent sedentary per day was 
significantly related to PPT performance at discharge (r = -0.37; p = 0.05), but not the 6MWT or 
TUG.  Discussion and Conclusions:  Patients with acute stroke were sedentary most of their 
hospital stay.  Mean time spent sedentary per day was associated with poorer performance at 
discharge on the PPT, but not the 6MWT and TUG.  Patients with acute stroke may benefit from 




Low levels of activity have been documented in those hospitalized for an acute illness 
other than stroke (Brown et al., 2004; Brown et al.; Lazarus et al., 1991).  Inactivity during 
hospitalization has been associated with functional decline that necessitated nursing home 
placement even for those who resided in the community prior to hospitalization.  Further, 
inactivity during hospitalization of older adults recovering from a medical illness is an “under-
recognized epidemic.”  Brown and colleagues monitored activity continuously (24 hours/day) 
using accelerometers and reported that older adults recovering from an acute illness in the 
hospital spend approximately 83% of their day lying in bed despite being able to walk 
independently during their hospital stay (Brown et al., 2009). 
In trying to understand activity patterns during stroke recovery, observational studies 
have examined activity during inpatient stroke rehabilitation and have reported high levels of 
sedentary time (Askim et al., 2014; Bernhardt et al., 2008).  When observing activity in 10 
minute intervals from 8:00 am to 5:00 pm, patients during in-patient stroke rehabilitation were 
seen in bed or sitting 76% of the day and standing or walking 23% of the day (Bernhardt et al., 
2008).  Further, greater time spent in bed has been associated with a poorer outcome on the 
modified Rankin Scale (mRS) at 3 months post-stroke (Askim et al., 2014).  This evidence 
suggests that during an inpatient rehabilitation stay, individuals after stroke are spending a large 
majority of their time engaging in sedentary behavior, which could have a negative impact on 
functional recovery.  Because the acute stroke hospital length of stay in the United States (U.S.) 
is considerably shorter than those conducted in the early mobilization trials (~14 days) 
(Bernhardt et al., 2007; Cumming et al., 2011), it is imperative that we better understand activity 
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patterns during the acute stroke hospital stay in the U.S. so that we can consider strategies aimed 
at decreasing sedentary time. 
Direct observation of people hospitalized with acute stroke is an acceptable method for 
describing activities performed during the day.  However, this has the potential to miss any 
physical activity, which can limit the interpretation of these findings and may not accurately 
characterize the degree of inactivity.  For example, the observation studies in people with stroke 
have typically been conducted during the weekday and during usual work hours (i.e.: 8:00 am to 
5:00 pm) (Askim et al., 2014; Bernhardt et al., 2007; Bernhardt et al., 2008).  This limits 
documentation of activity in the evening hours, nighttime, or on weekends.  However, using an 
objective measure such as accelerometry would allow for continuous 24-hour monitoring 
(including sleep hours) without additional personnel burden for observation of activity.  The 
accelerometers can also provide information on intensity of activity such as light or vigorous 
activity and steps.  Additionally, twenty-four-hour monitoring with the use of accelerometers 
provides accurate characterization of physical activity patterns in patients with acute stroke.  To 
our knowledge, no objective quantification of physical activity using accelerometers has been 
conducted during the acute stroke hospital stay in the United States. 
Therefore, the purpose of this study was to objectively assess sedentary time using tri-
axial accelerometers during the acute hospital stay in individuals with stroke.  We examined 
whether the amount of time sedentary was related to functional performance at discharge.  A 
study demonstrated that older adults hospitalized on the medical floor spend 83% of their time 
lying in bed (Brown et al., 2009).  Therefore, we hypothesized that individuals with acute stroke 
would spend more than 80% of their hospital stay sedentary.  Further, we hypothesized that 
greater mean time spent sedentary over a course of a day would be moderately and significantly 
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related to poorer functional performance on the Physical Performance Test (PPT), 6 Minute 
Walk Test (6MWT), and Timed-Up and Go (TUG) at discharge from the hospital. 
 
2.3. Methods 
2.3.1. Study Design 
This study used a prospective design with a sample of convenience.  Approval of the 
project was obtained from the Human Subjects Committee at KU Medical Center.  Institutionally 
approved written informed consent was obtained prior to study participation. 
 
2.3.2. Participants 
Participants were enrolled into the study within 24 – 48 hours of their admission to the 
certified Comprehensive Stroke Unit at KU Hospital with a diagnosis of acute stroke.  
Participants were admitted into either the neurological progressive care or neurological intensive 
care units of the hospital.  Patients who are suspected of, or diagnosed with, stroke are 
commonly admitted to these floors.  The neurological progressive care unit is staffed with 1 
nurse for every 4 patients and several nursing aids across the floor.  The intensive care unit is 
staffed with 1 nurse for every 2 patients as well as several nursing aids.  Rehabilitation services 
are available 7 days per week.  Therapy services on the weekends were identical in duration and 
intensity to those provided during the week day.  A comprehensive list of participant 
demographics can be found in Table 2.1.  Individuals were eligible for the study if they were 
within 48 hours of admission to KU Hospital with a diagnosis of stroke and between the age of 
20 and 80 years.  Individuals were excluded if they were on physician ordered bed rest. 
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Table 2.1 Participant Demographics 
Characteristics, n = 32 Number or Sample Mean (SD) Range 
Male/Female 18/14 
Age (years) 56.5 (12.7) (29 – 80) 
Body Mass Index 28.3 (5.2) (16.9 – 39.3) 
National Institutes of Health Stroke Scale 3.7 (4.6) (0 – 21) 
Lower Extremity Fugl Meyer Score 25.5/34 (10.1) (0 – 34) 
Days of Activity Monitoring 2.5 (0.9) (1 – 4) 
Race/Ethnicity 
White/Caucasian 23 
African American 5 
Hispanic 2 
Asian 1 
Native American 1 
Functional Performance Baseline Discharge 
Physical Performance Test score 15.3/36 (10.3) 18.7/36 (11.6) 
6 Minute Walk Test (meters) 126.8 (131.8) 191.1 (150.4) 






After consent an ActiGraph (ActiGraph LLC. Pensacola, FL) GT3X+ tri-axial 
accelerometer was placed on the stroke-affected limb at the ankle.  When the Fugl-Meyer score 
was 34/34 on both legs (n = 6), we collected data from the right ankle.  The Actigraph GT3X+ is 
more reliable when placed on the ankle vs the hip or spine to measure step count in older adults 
with and without an assistive device (Korpan et al., 2014). 
The water-resistant accelerometers were worn for 24 hours per day until the day of 
discharge from the hospital, but no longer than 4 days.  This timeframe was selected as the 
maximum length apriori since the average length of stay at KU Hospital for people with acute 
stroke was 4 days.  Our research team would check on the participants throughout the day to 
make sure the accelerometers were correctly placed and the participants were comfortable with 
wearing the accelerometers.  Nursing staff was given our 24-hour hotline number and if any 
issues such as non-compliance or skin irritation occurred, they would leave a message and the 
team would follow up. 
ActiGraph GT3X+ accelerometers used 10-second epochs to monitor 24 hour, real-time 
activity in all three planes of movement.  Analysis of sedentary time was performed using 
ActiLife Version 6.6.3 (ActiGraph® L.L.C. Pensacola, FL) and included time spent in sedentary, 
light, moderate, and vigorous activity, steps per day, and time sedentary per day (TSPD) in 
minutes.  One day was defined as each 24-hour period starting immediately after consent.  For 
example if a person was consented at 3pm, a day would be defined from 3:00 pm until 2:59 pm 
the next day and each day thereafter until discharge.  If discharge occurred prior to a “day” then 
sedentary time was calculated based on the time the accelerometers were worn and not a full 24 
hour period as this would bias results.  Cut points for intensity of activity were based on 
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information previously reported and validated in adults (Freedson et al., 1998).  These were 
based on the following: light, < 1951 counts; moderate, 1952 – 5724 counts; and vigorous 
activity, >5725 counts (Freedson et al., 1998).  Sedentary time was defined as any activity that 
does not amount to more than <99 counts per ActiLife software.  Baseline functional 
assessments were performed after placement of accelerometers.  Follow-up testing was 
conducted on the day of discharge or four days after baseline testing, whichever came first. 
Information regarding participants’ lesion size and location, previous medical history, 
current medications, weight, height, and BMI were obtained from each participant’s electronic 
health record.  In addition, we gathered information regarding their physical and occupational 
therapy minutes.  The Fugl-Meyer Assessment (FMA) was used to assess motor performance of 
the lower extremity (Sanford et al., 1993).  Total score on the lower extremity FMA is 34, and a 
higher score is indicative of lower stroke impairment.  Functional assessments included: PPT, 
6MWT, and TUG. 
The PPT, an assessment of performance of activities of daily living (ADLs), is a valid 
and reliable test used in many populations including individuals with dementia and Parkinson’s 
disease and those who are elderly (Delbaere et al., 2006; Farrell et al., 2011; Kernan et al., 2005; 
Lusardi et al., 2003; Reuben,Siu, 1990).  Although data has not been published in acute stroke, 
the PPT has been used in individuals who have experienced transient ischemic attack and stroke 
(Kernan et al., 2005).  The PPT is a test in which the participant is asked to complete 9 tasks of 
activities of daily living.  Each task is timed and then score on a scale of 0 – 4 depending on their 
time, with 0 indicating unable to complete the task without assistance and 4 indicating 
completion of the task in the fastest time category.  The total score on the PPT is 36, with a 
higher score indicative of better performance in activities of daily living.  The 6MWT was 
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performed according to previous guidelines outlined by the American Thoracic Society (Crapo et 
al., 2002).  Individuals are asked to walk as far as they can for 6 minutes and the distance walked 
in meters is recorded.  A longer distance walked in 6 minutes is indicative of better walking 
endurance.  Methods of the motor portion of the FMA and the TUG have been described 
previously (Podsiadlo,Richardson, 1991; Sanford et al., 1993).  For the TUG, individuals start the 
test in a seated position.  They are instructed to stand up, walk 3 meters to and around a cone, 
walk back to the chair, and sit down.  A faster time on the TUG is indicative of higher functional 
mobility.  Participants were allowed to rest as needed between functional tasks. 
 
2.3.4. Data Analysis 
Descriptive statistics were performed to obtain sample mean percent time spent in 
sedentary, light, moderate and vigorous activities, sample mean steps per day (SPD), sample 
mean time sedentary per day (TSPD), sample mean score on PPT, sample mean distance on the 
6MWT, and sample mean time on the TUG.  Mean percent time spent in sedentary, light, 
moderate, and vigorous activities is reported as an overall percent time over the duration of the 
hospital stay across participants.  Mean time sedentary per day is expressed as 100 * (total 
minutes spent in sedentary time * total minutes-1).  To assess the relationship between TSPD and 
functional performance of each variable (PPT, 6MWT, and TUG) at discharge we used a Pearson 
Correlation.  To understand the strength of the relationship between TPSD and functional 
performance, we used criteria defined by Portney and Watkins (LG,MP, 1993): Pearson’s 
coefficient (r) = 0.00 – 0.25, little to no relationship; r = 0.25 – 0.50, fair relationship; r = 0.50 – 
0.75, moderate to good relationship; and r >0.75, good to excellent relationship. Since admission 
(or baseline) functional scores are important predictors of discharge scores in stroke (Pohl et al., 
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2013), we took a more conservative approach and controlled for baseline performance in our 
data analysis of the respective functional assessments.  Statistical methods for the linear 
regressions were based off of methods previously used (Vidoni et al., 2012).  Briefly, we used a 
multistep, hierarchical linear regression with TPSD as the predictor variable and the PPT score at 
Time 2 as the response variable controlling for baseline PPT performance.  Standardized 
residuals generated from the linear regression were then plotted.  P-values were considered 
significant at p < 0.05.  All statistical analyses were performed using IBM SPPS® Statistics 
Software Version 20 (Armonk, New York). 
 
2.4. Results 
We screened 683 individuals with an acute stroke and enrolled 38 participants in our 
study.  Of the 38 enrolled participants, six were not included in the analysis.  The reasons for 
non-enrollment and exclusion from data analysis are outlined in Figure 2.1.  Thirty-two people 
(18 males; mean age of 56.5 + 12.7 years) were used for data analysis except for the Timed Up 
and Go (n = 23).  If participants could not stand up from the chair using the armrests to initiate 
walking, they were coded as “unable” and not included in the data analysis examining the 
relationship between sedentary time and functional performance at discharge.  These individuals 
were included in the primary aim, which was describing activity during the acute hospital stay. 
Participants spent a mean of 2.5 + 0.9 days enrolled in our study.  Twenty-eight 
individuals were discharged from the hospital prior to 4 days of enrollment.  Therefore, 6 
individuals completed 4 full days of accelerometer monitoring.  Additionally, 8 individuals were 
enrolled the same day as their admission to the hospital and 26 were enrolled after their 
admission date, but within 48 hours. 
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Figure 2.1. Participant Enrollment Flow Chart 
 




2.4.1. Characterization of Sedentary Time 
Our results show that people after acute stroke spend the majority of their time sedentary 
and almost no time in moderate or vigorous activity (see Table 2.2).  Participants took a mean of 
1907 + 1594 steps per day.  On average, 22.6 + 15.9 minutes per day were spent in physical 
therapy and 15.2 + 12.7 minutes per day were spent in occupational therapy.  The total 
accumulated therapy minutes for physical and occupational therapy are presented in Table 2.2. 
Sedentary behavior per hour was lowest during the hours of 9:00 – 11:00 am and 2:00 – 
4:00 pm.  Between the hours of 9:00 and 11:00 am, mean percent time spent sedentary per hour 
was at its lowest at 91% (Figure 2.2) while light activity accounted for 7%.  During this time, 
participants walked a mean of 337 steps per hour. 
 
Table 2.2. Activity Characterization and Functional Performance 
n = 32 Number or Sample Mean (SD) Range 
Daily Mean Percent Time in Activities 
Sedentary 93.9 (4.1) (80 – 99) 
Light 5.1 (2.4) (0 – 10) 
Moderate 0.7 (0.7) (0 – 3.3) 
Vigorous 0.2 (0.4) (0 – 1.4) 
Time Sedentary per Day (minutes) 1354.7 (58.6) (1154 – 1428) 
Total Accumulated Therapy Minutes 
Physical Therapy 53.6 (50.6) (0 – 230) 




Figure 2.2. Daily Sedentary Activity Pattern 
 
Figure 2.2. Graph of mean percent time spent sedentary per hour over the course of the day 
 
2.4.2. Sedentary Time and Functional Outcome 
Baseline performance for all functional measures is presented in Table 2.2.  A multistep 
hierarchical linear regression revealed a significant, weak relationship between TSPD and 
discharge performance on the PPT (r = -0.37; p = 0.05) when adjusting for baseline performance 
(Figure 2.3).  However, when examining the relationship between TSPD and discharge 
performance on the 6MWT (r = -0.20; p = 0.29) and TUG (r = 0.23; p = 0.37), no significant 
relationship was observed when adjusting for baseline performance.  From baseline to discharge, 




Figure 2.3. Time Sedentary per Day vs. PPT Score at T2 
 
Figure 2.3. Scatter plot of the time sedentary per day plotted against performance on the PPT at 
Time 2.  Longer times in sedentary behavior are associated with poorer performance on the PPT 
at discharge (r = -0.37; p = 0.05).  Variables are adjusted for performance on PPT at Time 1. 
 
2.5. Discussion 
The primary finding of this study was stroke patients spend the majority of the acute 
hospital stay sedentary.  To our knowledge, this is the first study within the U.S. healthcare 




2.5.1. Characterization of Sedentary Time 
We hypothesized that stroke patients would spend 80% of their time sedentary as 
measured by accelerometers.  We reported that the mean daily time spent sedentary was 
approximately 94% of their hospital stay.  Our findings are similar to previous observational 
studies during in-patient rehabilitation in that the majority of the time is spent sedentary 
(West,Bernhardt, 2013).  Our study differs from previous studies in that we used accelerometers 
to continually assess activity level rather than behavioral mapping and observation 
(West,Bernhardt, 2013). 
Although the percent of time spent sedentary per day is high (94%) or 22.5/24 hours 
sedentary, this does include nighttime when patients are sleeping.  This allowed us to capture all 
movement and activity during a 24-hour period in a continuous and objective manner without 
adding bias through observation.  Typically, adults 60 years of age and older sleep for an average 
of 7.4 hours (30% of their day) between the hours of 10:48 pm + 1 hour and 6:54 am + 1 hour 
(Klerman,Dijk, 2008).  Sedentary time for our participants was highest within the timeframe that 
was reported by Klerman and colleagues (Klerman,Dijk, 2008).  However, some of our 
participants were not completely sedentary during usual times of sleep (see Figure 2.2). 
Our study suggests that people hospitalized with an acute stroke spend a higher 
percentage of time sedentary than what is reported in the literature for an acute medical illness 
(Brown et al., 2009).  Given the negative effects of inactivity, patients with acute stroke appear 
to be at even greater risk for complications.  Bed rest studies have demonstrated negative 
vascular adaptations (Bleeker et al., 2004) and loss of muscle mass which decreases muscle 
strength (Kortebein et al., 2007).  Considering their low cardiopulmonary fitness levels in acute 
stroke (Mackay-Lyons,Makrides, 2002), and that the low intensity during rehabilitation is not 
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sufficient for cardiopulmonary health (MacKay-Lyons,Makrides, 2002), efforts to increase 
physical activity and minimize decline from sedentary behavior should be encouraged.  
Therefore, using a multidisciplinary team approach to reduce sedentary time such as early 
mobilization during the acute hospital stay may slow the further decline of cardiopulmonary 
health and allow people post-stroke to engage more efficiently in rehabilitation.  Due to the 
stroke-related impairments that often exist, such as hemiparesis and loss of muscle mass (Ryan et 
al., 2011; Ryan et al., 2002), novel strategies for decreasing the amount of time spent sedentary 
in the hospital are critical.  Further, the recent publication from the American Heart 
Association/American Stroke Association for Physical Activity and Exercise Recommendations 
for Stroke Survivors suggests that we need to better understand physical activity patterns during 
acute stroke and conduct research to gain a better understanding of a dose response to “slow or 
prevent loss of cardiopulmonary fitness (Billinger et al., 2014).” 
While our study is the first to use accelerometers in acute stroke, others have examined 
physical activity during inpatient rehabilitation and community living.  Prajapati and colleagues 
used accelerometers to asses self-selected walking activity in subacute stroke in one single day 
on the inpatient rehabilitation unit (Prajapati et al., 2013).  The 8 participants ranged from 13 
days to 68 days post-stroke and all could ambulate with or without an assistive device 
independently.  The authors report that while their participants were independent with their 
ambulation (with/without assistive device), they spent little time (about 10%) of their day in 
activity such as walking.  This similar pattern appears to remain consistent when individuals 
post-stroke return home.  Roos and colleagues monitored walking activity using activity 
monitors in people post-stroke and otherwise healthy older adults dwelling in the community 
(Roos et al., 2012).  Their findings also support that community-dwelling individuals spend less 
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time in bouts of walking during the day after stroke when compared to healthy adults.  Our data 
suggest that sedentary time begins during acute stroke recovery.  Therefore, physical therapists 
and other healthcare providers should work with people after stroke to minimize inactivity and 
meet the recommended minutes for physical activity and exercise (Billinger et al., 2014). 
 
2.5.2. Sedentary Time and Functional Outcome 
This is the first study to examine the relationship between sedentary time using 
accelerometry and functional performance measures.  We hypothesized that we would see a 
moderate correlation between functional outcome measures and sedentary time.  Baseline 
performance likely influences performance at discharge.  Therefore, we chose to be conservative 
and control for baseline performance on all outcome measures in our analysis.  We report that 
the PPT had a fair and significant relationship with sedentary time.  This may be due to the 
comprehensive activities (balance, walking, feeding, dressing) that are included in the PPT.  The 
6MWT and TUG (n = 23) had little to no relationship with sedentary time.  The 6MWT and 
TUG are walking activities and perhaps not sensitive to detecting change in a few days following 
an acute stroke.  We must also consider that sedentary time may be higher early after stroke as 
patients are being evaluated by the therapy team regarding walking performance.  Therefore, 
people after stroke may not be encouraged to move about during this time or wait until therapy 
or nursing is available to assist. 
There are several limitations to the study that must be considered when interpreting 
results.  The sample size for this pilot study was small but provides preliminary data to inform 
large scale studies of in-hospital sedentary time and the relationship to functional outcome 
measures such as the 6MWT and TUG.  We used the device on the ankle, which appears to 
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provide the most accurate measure for step counts.  However, our primary outcome was physical 
activity levels and we do not know how accurate the device is for assessing this specific 
parameter.  We did not track the time of day that physical and occupational therapy occurred.  
Therefore, we do not know how much “activity” time was self-initiated or occurred during 
therapy time but our data does provide information regarding continuous activity during the 
acute hospital stay.  The PPT is a measure of physical performance and consists of simulated 
activities of daily living but has not been validated in stroke.  Finally, we did not gather 
information regarding other comorbidities or prior orthopedic injury, joint replacement, or low 
back pain.  It is possible that comorbid conditions could have contributed to reduced mobility 
during the stroke hospital stay. 
Future work should begin to elucidate the benefits of early physical activity and how 
stroke recovery may benefit from incorporating physical activity early after stroke.  A recent 
review by Zeiler and Krakauer made several excellent points regarding the importance of the 
“sensitive period” in the early phase of stroke recovery (Zeiler,Krakauer, 2013).  The authors 
discussed the available literature suggesting that enriched environments and engaging in activity 
(task specific training) enhances recovery from stroke.  The data we present suggest that early 
after stroke the majority of the stroke patients are sedentary and are not spending their time 
engaging in activity that could be optimal for recovery.  Most of the activity occurred early in the 
morning, which again leaves the remainder of the day inactive and likely alone in their room.  
Considering ways to encourage more activity whether through early mobility or spending time 






Acute stroke patients are sedentary the vast majority of their time sedentary while in the 
hospital.  Further, sedentary time was inversely related to performance in our outcome measures.  
Given the well-documented and rapid onset of the negative effects of inactivity, our data suggest 
that there needs to be a focus of reducing inactivity upon admission.  Therapists, with their 
clinical understanding of movement after stroke, are key providers to initiate and guide 
increasing activity and mobility.  
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3. CHAPTER 3. USE OF A NON-EXERCISE ESTIMATE 
FOR PRE-STROKE PEAK VO2 DURING THE ACUTE 
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Purpose: In individuals with acute stroke it is difficult to conduct an exercise test to assess peak 
oxygen consumption (peak VO2).  Therefore, the purpose of this study was to use a clinically 
feasible tool for assessing pre-stroke peak VO2 using a non-exercise estimation equation to test 
whether estimated pre-stroke peak VO2 was related to functional outcome measures at discharge 
from the hospital in individuals following an acute stroke.  We hypothesized that estimated pre-
stroke peak VO2 would be significantly related to discharge Physical Performance Test (PPT), 
Six-Minute Walk Test (6MWT), and lower extremity Fugl-Meyer (LEFM).  Methods:  
Estimated pre-stroke peak VO2 was calculated using a previously validated prediction equation 
using the following variables: BMI, age, gender, resting heart rate, and a self-reported measure 
of physical activity.  Outcome measures were assessed 4 days after enrollment or immediately 
prior to discharge (whichever occurred first). Results:  Thirty-four participants (56.0 + 12.6 -
years; 20 males) with acute stroke were enrolled within 48 hours of admission.  For all 
individuals, estimated pre-stroke peak VO2 was 27.3 + 7.4 mL*kg-1*min-1 and had a weak, non- 
significant relationship with the PPT (r = .19; p = .28), 6MWT (r = .10; p = .56), and LEFM (r = 
.32; p = .06).  However, when considering sex, females but not males had a significant 
relationship with LEFM (r = .73; p = .005) and moderate but non-significant relationship with 
PPT (r = .53; p = .06) and 6MWT (r = .47; p = .10).  Conclusions:  Within 48 hours of stroke 
admission, we were able to administer a non-exercise equation to estimate pre-stroke peak VO2.  
For the entire sample, functional measures conducted at discharge were not related to estimated 
pre-stroke peak VO2.  However, when considering sex, the relationship between pre-stroke VO2 





Individuals post-stroke are physically inactive, spend small amounts of time walking per 
day (Roos et al., 2012), and have poor cardiorespiratory (CR) fitness, defined as peak oxygen 
consumption (peak VO2) (Billinger et al., 2012; Gordon et al., 2004; Mackay-Lyons,Makrides, 
2002; Macko et al., 1997).  Assessing peak VO2 using a metabolic cart with gas analysis is 
considered the gold standard (ACSM, 2010).  Peak VO2 may be an indicator of one’s ability to 
participate in varying levels of activity such as exercise and activities of daily living (ADLs), 
especially in older adults (Billinger et al., 2011; Fleg et al., 2013) and people after stroke 
(Gordon et al., 2004).  However, peak exercise testing is difficult, if not impossible, to conduct 
during the acute stroke hospital particularly with shorter lengths of stay especially in the United 
States.  In our previous work, we reported an average of 2.5 days for an acute stroke hospital stay 
(Mattlage et al., 2015).  This combined with ongoing medical diagnostic testing, patient fatigue, 
and neuromotor impairments makes exercise testing difficult.  Therefore, using non-exercise 
measurements, such as prediction equations, to estimate peak VO2 could be a simple, low-cost 
alternative to healthcare providers and especially physical therapists during the acute stroke 
hospital stay. 
The American Heart Association published a scientific statement, The Importance of 
Cardiorespiratory Fitness (VO2 max) in the United States, which highlights that CR fitness is 
recognized as an important marker of both functional ability and cardiovascular health 
(Kaminsky et al., 2013).  Furthermore, CR fitness is currently the only major risk factor that is 
not routinely and regularly assessed (Kaminsky et al., 2013).  People post-stroke already have 
poor CR fitness in the acute stroke setting (MacKay-Lyons,Makrides, 2002) and our work has 
demonstrated that a high percent of the acute hospital stay is spent sedentary (Mattlage et al., 
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2015).  Therefore, using a previously validated, non-exercise estimation for peak VO2 may be a 
feasible option for rehabilitation professionals to assess CR fitness during the acute hospital stay 
when exercise testing may not be available or easily conducted and may be used as a marker of 
functional ability (Kaminsky et al., 2013). 
Jurca and colleagues developed and validated a prediction equation to estimate peak VO2 
in a large population of community dwelling, middle-aged adults (Jurca et al., 2005).  Their 
prediction equation was then cross-validated in a targeted older adult population (60-80 years of 
age) with 83.3% of the sample having between 1-6 cardiovascular (CV) risk factors and 15.7% 
having no CV risk factors (Mailey et al., 2010).  The measured VO2 max (21.58 mL*kg-1*min-1) 
and predicted VO2 max (21.42 mL*kg-1*min-1) were similar in this group of older adults.  This 
non-exercise prediction equation uses the following variables sex, age, body mass index (BMI), 
resting heart rate (rHR), and a self-reported measure of physical activity.  This equation would 
be simple and easy to use during the acute stroke setting and has clinical utility for estimating 
peak VO2. 
Having a measure of CR fitness using an estimated peak VO2 such as the Jurca equation 
allows for investigation into whether pre-stroke CR fitness is related to stroke recovery.  There is 
evidence in animal models that suggests exercise pre-conditioning protects against injury 
following myocardial ischemia (Calvert et al., 2011) and cerebral ischemia (middle cerebral 
artery occlusion followed by reperfusion) (Davis et al., 2007; Ding et al., 2006; Li et al., 2004; 
Liebelt et al., 2010).  In human studies (Deplanque et al., 2012; Krarup et al., 2008; Stroud et al., 
2009) physical activity prior to stroke may be neuroprotective and reduce stroke-related 
impairment as measured by the Barthel Index (BI) (Deplanque et al., 2012; Stroud et al., 2009) 
and modified Rankin Score (mRS) (Deplanque et al., 2012; Krarup et al., 2008). 
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The purpose of this study was to use a clinically feasible tool for assessing pre-stroke 
peak VO2 using a non-exercise estimation equation to test whether estimated pre-stroke peak 
VO2 was related to functional outcome measures at discharge from the hospital in individuals 
following an acute stroke.  We hypothesized a priori that, after controlling for lesion size, 
estimated pre-stroke peak VO2 would be moderately and significantly related to the Physical 
Performance Test (PPT), our primary outcome measure, and the Six-Minute Walk Test (6MWT) 
and the lower extremity Fugl-Meyer Assessment (LEFM), at discharge.  A post-hoc analysis was 
conducted to determine whether sex differences existed between estimated pre-stroke peak VO2 
and our outcome measures at discharge. 
 
3.3. Methods 
3.3.1. Study Design 
This study used a sample of convenience and included individuals admitted to KU 
Hospital with a diagnosis of acute stroke.  The study was approved by the Human Subjects 
Committee (HSC) at KU Medical Center and institutionally approved written informed consent 
was obtained from all participants prior to study enrollment. 
 
3.3.2. Participants 
Between the months of June 2012 and October 2013, 683 individuals admitted to KU 
Hospital with a diagnosis of acute stroke were screened for inclusion into the parent study, which 
has been published (Mattlage et al., 2015).  Individuals were enrolled if they were between 20 
and 80 years of age with a diagnosis of acute ischemic or hemorrhagic stroke.  Individuals were 
excluded if: 1) consent was not possible without a surrogate consent; 2) the individual was 
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unable to provide written consent within 48 hours of admission to the stroke unit; 3) discharge 
from the hospital was to occur before baseline assessments; and 4) the individual was prescribed 
to physician-ordered bed rest.  Table 3.1 outlines demographic characteristics of study 
participants.  Of the 683 individuals screened, 238 were ineligible due to anticipation of 
discharge prior to the study team conducting baseline testing, 113 were ineligible due to 
physician ordered bed rest, 112 were ineligible due to the time on the stroke unit exceeded 48 
hours prior to the study team initiating consent, 94 did not meet the inclusion criteria for age, 67 
were ineligible due to intubation or the inability to consent, and 21 individuals declined 
participation. 
 
3.3.3. Outcome Measures 
All functional performance outcome measures were assessed on either the fourth day 
following consent (Day 4) or on the day of discharge from the hospital, whichever occurred first 
(Mattlage et al., 2015).  A stroke neurologist performed the NIH Stroke Scale (NIHSS) on 
admission to the hospital.  A team radiologist (N.H.) calculated lesion volumes from structural 
magnetic resonance images (MRI) performed at admission to the hospital using established 
standardized neuroimaging techniques for ischemic and hemorrhagic stroke (Majersik et al., 
2015; Newman, 2007).  An ellipsoidal estimation function was used (Newman, 2007).  In cases 
of multiple lesions, largest lesion volume was used and all volumes are reported in centimeters 






3.3.3.1. Estimated Peak Oxygen Consumption (Peak VO2) 
We selected the previously established and validated equation by Jurca (Jurca et al., 
2005) and (MaileyMailey et al., 2010) based on data from our laboratory examining non-exercise 
estimated peak VO2 and measured peak VO2 in healthy adults (n = 110).  The results of our 
unpublished data were similar to prior reports (Jurca et al., 2005; Mailey et al., 2010) in that 
estimated peak VO2 was strongly correlated to measured peak VO2 (r = 0.88 p < 0.001).  Based 
on these data, we chose to use this non-exercise equation to estimate pre-stroke peak VO2 in 
people with acute stroke during the hospital stay. 
After consent in acute stroke participants, we recorded the necessary information for the 
Jurca equation (Jurca et al., 2005).  The Jurca equation uses the following variables to estimate 
pre-stroke peak VO2: age, sex, BMI, rHR, and a constant variable associated with the 
participants’ self-reported physical activity level prior to being admitted to KU Hospital for acute 
stroke.  The self-reported physical activity score is separated into five categories (Levels 1-5), 
with a constant variable assigned to each.  Each level considers a different duration, frequency, 
and intensity of activity performed in a typical week.  Information regarding participants’ 
activity levels are in Table 3.2.  The Jurca prediction equation is as follows: Estimated METS = 
[(Sex, F = 0; M = 1 x 2.77) – (Age in years x 0.10) – (BMI x 0.17) – (rHR x 0.03) + (Physical 
Activity Score x 1.00) + 18.07] (Jurca et al., 2005).  Estimated METS is multiplied by 3.5 
mL*kg-1*min-1 (1 MET = 3.5 mL*kg-1*min-1) (ACSM, 2010) to get estimated pre-stroke peak 
VO2. 
Although the Jurca prediction equation to estimate peak VO2 has not been validated in 
the acute stroke population, it has been previously validated in older adults with multiple CV risk 
factors (Mailey et al., 2010).  As mentioned the variables included in the Jurca equation are age, 
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sex, BMI, physical activity and rHR.  We did not expect BMI to change within 1-2 days post-
stroke.  Physical activity was assessed as “activities performed in a typical week prior to your 
stroke”.  However, resting HR could be influenced after a stroke.  Therefore, we wanted to 
ensure that the rHR at the time of stroke was appropriate to use.  To our knowledge, there is no 
information in the literature regarding whether rHR is similar before and after stroke.  Therefore, 
we examined the medical record of a small subset of the cohort which had rHR captured in the 
medical record before their stroke.  In these individuals (n=19), rHR was not significantly 
different before and after stroke (before stroke: 76.4 bpm + 10.8; after stroke: 76.4 bpm + 13.8; p 
= 0.983). 
 
3.3.3.2. Physical Performance Test (PPT) 
The PPT has been identified as a useful clinical tool and has demonstrated high inter-rater 
reliability and concurrent validity for measuring performance of ADLs in older adults and 
individuals with stroke (Reuben et al., 1995; Rozzini et al., 1997; Sherman,Reuben, 1998).  We 
previously used the 9-item version of the PPT in older adults with and without Alzheimer’s 
disease (Vidoni et al., 2012) and on the acute stroke unit (Mattlage et al., 2015).  The PPT 
includes tasks individuals complete on a daily basis such as: writing a sentence, simulate eating, 
lifting a book onto a shelf above shoulder height, putting on and removing a jacket, picking up 
an item from the floor, walking 50 feet, turning in a circle, rising from a chair 5 times without the 
use of the upper extremities, and a progressive Rhomberg test of balance (standing with feet 





3.3.3.3. Six-Minute Walk Test (6MWT) 
The 6MWT is a reliable and valid tool for assessing walking endurance in individuals 
after stroke (Eng et al., 2004; Flansbjer et al., 2005; Fulk,Echternach, 2008; Kosak,Smith, 2004; 
Patterson et al., 2007; Perera et al., 2006; Wevers et al., 2011).  The 6MWT was performed with 
minimal distractions on a 14-meter section of the walking track outside of the participants’ room 
on the stroke unit.  A 14-meter ribbon was secured to the floor and orange cones were placed at 
both ends.  A stopwatch was used to keep time and standardized verbal cues were given every 
minute according to previously published guidelines (Crapo et al., 2002).  All participants wore a 
gait belt during the test for safety.  If the tester needed to provide greater than minimal physical 
assistance with walking or if the participant needed to sit down to rest, the testing was terminated 
and the distance walked in that time was recorded.  Participants were allowed to use an assistive 
device (e.g. walker, cane) if needed during the test.  If a participant was unable to ambulate with 
or without an assistive device, a score of 0 meters was recorded. 
 
3.3.3.4. Fugl-Meyer Assessment (FMA) 
The FMA is a commonly used tool to measure motor performance and has been shown to 
be a valid and reliable tool in individuals post-stroke.Sanford et al., 1993  We collected data 
using only the lower extremity motor portion (LEFM), which was scored on a scale of 0 – 34, 







3.3.4. Sample Size Justification 
We calculated sample size for the parent study (Mattlage et al., 2015) and determined we 
needed 35 participants.  We allowed for a small attrition rate of 10% and therefore, planned to 
enroll a total of 38 individuals. 
 
3.3.5. Statistical Analysis 
Data analysis was performed using SPSS software Version 20.0 (SPSS Inc, Chicago, IL) 
for Windows.  We report data as mean (standard deviation) where appropriate.  All significance 
levels were set to a .05 alpha-level, with 95% confidence intervals (CI).  A partial correlation 
was performed to determine the relationship of estimated pre-stroke peak VO2 and functional 
outcomes (PPT, 6MWT, LEFM) while controlling for lesion size.  We chose to be conservative 
in our analyses and controlled for initial lesion size because of its potential influence on motor 
performance.  Additionally, to examine whether there might be sex differences in estimated pre-
stroke peak VO2 and our selected outcome measures, partial correlations were performed. 
 
3.4. Results 
In the parent study, we enrolled 38 participants with a total of 34 individuals completed 
the study and were used for data analysis (Table 3.1).  Mean time between study enrollment and 
performance of discharge assessments was 2.5 days. 
The majority of our participants reported engaging in light physical activity prior to 
stroke (Table 3.2).  Mean estimated pre-stroke peak VO2 was 27.3 (7.4) mL*kg-1*min-1 and is 
consistent with prior studies using measured peak VO2 (Billinger et al., 2012; MacKay-
Lyons,Makrides, 2002).  This supports prior evidence that people post-stroke had lower CR 
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fitness pre-stroke for their age, using ACSM categories.  Table 3.3 and Figure 3.1 demonstrate 
estimated pre-stroke peak VO2 and fitness level for gender and age. 
 





Table 3.1. Participant Demographics 
Characteristics, n = 34 Number or Group Mean (SD) 
Male 20 
Age (years) 56.0 (12.6) 
Race/Ethnicity 
Caucasian 24 
African American 5 
Hispanic 3 




Type 1 1 
Type 2 10 
Unknown 5 
NIH Stroke Scale on Admission 3.7 (4.4) 
Discharge Performance 
Physical Performance Test 18.9 (11.2) 
6 Minute Walk Test (meters) 199.7 (149.8) 
Lower Extremity Fugl-Meyer Score 27.4 (9.3) 




Table 3.2. Self-reported Physical Activity Scores 
Physical Activity Score, n = 34 Number Constant 
Level 1 6 0.00 
Level 2 19 0.32 
Level 3 5 1.06 
Level 4 0 1.76 
Level 5 5 3.03 
 
Table 3.2.  Level 1: Primarily sedentary; Level 2: Five days or more per week of light 
physical activity for 10 minutes or more at a time; Level 3: Moderate aerobic exercise for 20 
to 60 minutes per week; Level 4: Moderate aerobic exercise for 1 to 3 hours per week; Level 




Table 3.3. Estimated Pre-Stroke Peak VO2 Levels 
Age Group (years) n Group Mean (SD) mL*kg-1*min-1 ASCM Fitness Category 
ALL 34 27.3 (7.4) 
 26-35 2 25.3 (4.9) Very Poor 
 36-45 5 26.3 (7.0) Poor 
 46-55 9 33.2 (9.4) Average 
 56-65 9 24.9 (6.2) Poor 
 65+ 9 24.7 (4.1) Below Average 
MALES 20 31.3 (6.6) 
 26-35 0 
 36-45 3 31.0 (2.0) Average 
 46-55 6 38.7 (5.7) Good 
 56-65 4 30.4 (2.3) Average 
 65+ 7 25.5 (3.3) Average 
FEMALES 14 21.6 (4.1) 
 26-35 2 25.3 (4.9) Very Poor 
 36-45 2 19.2 (4.9) Very Poor 
 46-55 3 22.3 (0.9) Poor 
 56-65 5 20.5 (4.2) Poor 




The secondary objective was to determine whether predicted pre-stroke peak VO2 was 
related to the outcome measures at discharge.  The findings show that estimated pre-stroke peak 
VO2 was weakly, but not significantly, related to discharge outcome scores for the PPT (r = 0.19, 
p = 0.28, CI [-.14, .48]), 6MWT distance (r = 0.10, p = 0.56, CI [-.24, .45]), and LEFM scores (r 
= 0.32, p = 0.06, CI [-.03, .61]) when controlling for initial lesion size.  When separating data for 
sex and controlling for initial lesion size, estimated pre-stroke peak VO2 in males did not have 
any significant relationships with functional measures (PPT: r = .13, p = .60, CI [-.32, .55]; 
6MWT: r = .05, p = .82, CI [-.44, .59]; LEFM: r = .15, p = .54, CI [-.35, .57]).  Estimated pre-
stroke peak VO2 in females showed a strong, significant relationship with LEFM (r = .73, p = 
.005, CI [.41, .96]) (Figure 3.2), but moderate, non-significant relationships with the PPT (r = 
.53, p = .06, CI [-.13, .91]) (Figure 3.3), and 6MWT (r = .47, p = .10, CI [-.14, .91]) (Figure 3.4) 
when controlling for initial lesion size.  
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Figure 3.2. Estimated Pre-Stroke Peak VO2 vs. Discharge FMA Score 
 
Figure 3.2.  Scatter plot of estimated pre-stroke peak VO2 residuals plotted against FMA score at 
discharge separated by gender.  (Males: r = .15, p = .54, CI [-.35, .57]; Females: r = .73, p = .005, 
CI [.41, .96]).  Higher estimated pre-stroke peak VO2 in females is significantly related to FMA 
score at discharge.  Variables are adjusted for lesion volume calculated from the admitting MRI. 
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Figure 3.3. Estimated Pre-Stroke Peak VO2 vs. Discharge PPT Score 
 
Figure 3.3.  Scatter plot of estimated pre-stroke peak VO2 residuals plotted against PPT score at 
discharge separated by gender.  (Males: r = .13, p = .60, CI [-.32, .55]; Females: r = .53, p = .06, 
CI [-.13, .91]).  Variables are adjusted for lesion volume calculated from the admitting MRI. 
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Figure 3.4. Estimated Pre-Stroke Peak VO2 vs. Discharge 6MWT Distance 
 
Figure 3.4.  Scatter plot of estimated pre-stroke peak VO2 residuals plotted against 6MWT 
distance at discharge separated by gender.  (Males: r = .05, p = .82, CI [-.44, .59]; Females: r = 
.47, p = .10, CI [-.14, .91]).  Variables are adjusted for lesion volume calculated from the 




This study used a non-exercise estimation equation to predict pre-stroke peak VO2 as an 
assessment of CR fitness in people with acute stroke during their hospital stay.  The mean length 
of stay for our participants was 2.5 days, which may make conducting an exercise test during the 
acute hospital stay difficult.  Previous data support that approximately 50% of patients with acute 
stroke return home (Pohl et al., 2013) and do not receive any information regarding CR fitness.  
These findings support prior work that CR fitness is low in acute stroke, specifically among 
women (MacKay-Lyons,Makrides, 2002).  Using a non-exercise estimation of peak VO2 would 
allow rehabilitation professionals, such as physical therapists, the opportunity to evaluate and 
discuss with their patients the importance of a prescribed home exercise program, where 
appropriate. 
In humans, there is some suggestion that pre-stroke physical activity can have a positive 
effect on stroke recovery at 8 days (Deplanque et al., 2012), 3 months (Stroud et al., 2009), and 2 
years (Krarup et al., 2008) after stroke.  One study enrolled participants within 30 days of stroke 
and asked about their physical activity levels during the year prior to their stroke.  The outcome 
measures were collected by telephone at 2 months post-stroke and were “dichotomized into 
‘good’ and ‘bad’ categories according to instrument-specific cut-points” (Stroud et al., 2009).  
They report that individuals who engaged in moderate or high levels of activity were more likely 
to have a “good” outcome at 3 months post-stroke.  Based on the evidence in the literature and in 
an attempt to better understand the relationship between CR fitness and stroke recovery, we 
conducted this study.  We hypothesized that estimated pre-stoke peak VO2 would be moderately 
and significantly related to discharge PPT, 6MWT, LEFM, when controlling for initial lesion 
size.  Our reported results did not support our hypothesis.  Our results showed only a weak, non-
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significant correlation between estimated pre-stroke peak VO2 and two of our outcome measures 
at discharge.  This could be due to over- or under-estimation of physical activity prior to stroke. 
This would influence the predicted peak VO2.  The acute stroke period is a sensitive time where 
an individual may not remember their typical physical activity.  It is possible that males and 
females may account for daily physical activity differently.  Therefore, in a post-hoc analysis, we 
examined whether sex differences exist between estimated pre-stroke VO2 peak and functional 
performance at discharge. 
A novel finding was the sex differences related to estimated pre-stroke peak VO2 and our 
functional outcome measures.  Our results indicated in females that estimated pre-stroke peak 
VO2 was related to functional outcomes but only the LEFM was statistically significant.  There 
was no relationship between estimated pre-stroke peak VO2 and functional outcome measures in 
males.  These results could be due to an over-estimation in self-selected physical activity levels 
in males or underestimation in females.  There could be an influence of stroke size and location 
between males and females.  We did control for the initial lesion size but we acknowledge that 
lesion location could influence functional performance such as walking in the 6MWT.  We also 
acknowledge participant fatigue could have influenced individual performance on our functional 
measures especially the 6MWT, which measures walking endurance.  We worked with the 
hospital therapy team to coordinate our testing with therapy sessions to avoid overlap, but 
previous therapy sessions could have affected performance.  In addition, the day of discharge 
from the acute hospital stay was busy with the participant leaving and could have affected patient 
performance.  It is important to acknowledge that our study was likely underpowered when 
considering previous work where the sample sizes were much larger (Deplanque et al., 2012; 
Stroud et al., 2009). 
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This pilot data will provide important information so that future work can be adequately 
powered to determine whether estimated pre-stroke peak VO2 is related to outcome measures 
such as the PPT or walking endurance (6MWT) and has laid the foundation for future work.  The 
Jurca equation to estimate peak VO2 has provided an objective measure for CR fitness in people 
post-stroke.  Although we did not compare the predicted peak VO2 to a measured VO2, one 
previous study by McAuley and colleagues found that these measures were correlated in older 
adults with chronic disease (McAuley et al., 2011).  The authors used the Jurca equation to 
investigate the association of the non-exercise estimation of peak VO2 measures of 
cardiorespiratory fitness (maximal exercise test and 1-mile timed walk) (McAuley et al., 2011).  
They found that the estimation equation was significantly correlated with the maximal exercise 
test and the 1-mile timed walk.  McAuley suggests that their results serve as evidence that the 
Jurca equation has utility in other populations, but that future work needs to be done to determine 
whether relationship exist in other domains.  The current work adds to this literature by 
describing the relationship of the Jurca non-exercise prediction equation and measures of 
function in a small sample of individuals with acute stroke.  McAuley highlights that assessing 
CR fitness is important in both healthy and diseased populations and may give deeper insight 
into other domains of health and acknowledge that exercise testing in older adults and 
individuals with high cardiovascular risk is difficult because of the risks involved, time 
constraints, and expenses such as obtaining proper equipment, personnel, and medical oversight.  
Therefore, we believe that there is a need for a short, non-exercise estimation of VO2 that is 
easily obtained in the acute, clinical setting. 
This study is novel in several ways.  First, we enrolled individuals after stroke within 48 
hours of admission to the stroke unit, where previous work has only enrolled participants within 
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the first 30 days (Stroud et al., 2009) or between 5 and 24 days after stroke (Krarup et al., 2008).  
Second, rather than using a Likert scale for physical activity, we chose to utilize a continuous 
measure of CR fitness, non-exercise estimated peak VO2, which incorporates many variables, 
including sex, age, self-reported physical activity, and rHR.  We acknowledge that rHR may be 
different pre- and post-stroke, though we demonstrated in a subset of our participants that rHR 
was not significantly different following stroke when compared to the participant’s pre-stroke 
data.  Due to the small sample, we acknowledge that these data may not be generalizable to all 
people after stroke. 
We then examined the relationship between estimated pre-stroke peak VO2 and selected 
outcome measures at discharge from the hospital.  While most studies have used categorical 
levels of self-reported physical activity, the intention was to be more specific by using peak VO2, 
a continuous variable.  To our knowledge, this is the first investigation to examine the 
relationship between estimated pre-stroke peak VO2 and objective measures of functional 
outcome at discharge from an acute stroke unit. 
This pilot study is the first study conducted in acute stroke using an estimated peak VO2 
prediction equation.  This data provides important information for assessing CR fitness as 
recommended in the publication, The Importance of Cardiorespiratory Fitness (VO2 max) in the 
United States (Kaminsky et al., 2013).  The data have provided a foundation for future work to 
rigorously examine the relationship between peak VO2 (estimated or measured) and outcome at 







We must address the large number of participants not enrolled and the potential for 
systematic bias.  We did have participants (n = 113) on bed rest while 238 were ineligible due to 
anticipation of discharge prior to the study team conducting baseline testing.  We recognize that 
this may appear to be a systematic bias towards non-enrollment for those with severe and mild 
stroke, which would bias the study towards accepting the null hypothesis.  The reason for non-
enrollment lies with the parent study (Mattlage et al., 2013), for which we aimed to consent, 
perform baseline testing, and equip accelerometers all within 48 hours of admission to the 
hospital.  Participants also needed a confirmed diagnosis of stroke by neuroimaging.  The 
challenge we faced was the short lengths of stay (mean 2.5 days) for all patients regardless of 
stroke severity.  If the study team was unable to consent and conduct the baseline testing within 
48 hours, many potential participants were not approached for consent.  This could have been 
due to the individual unavailable such as out for other medical tests, our study team did not get 
the neuroimaging report within 48 hours or we had current participant testing and could not 
screen and consent with the potential participant in a timely manner.  We believe we enrolled 
participants with a wide range of function from mild to severe stroke (Table 3.1 and Figure 3.2, 
Figure 3.3, and Figure 3.4).  It is important to note that while the functional performance of 
participants at discharge is varied, the propensity for low peak VO2 values especially in females 
is observed across the x-axis for estimated pre-stroke VO2 (Figure 3.2, Figure 3.3, and Figure 
3.4).  This may be a result of an underestimation of physical activity prior to stroke or people 
who have a stroke tend to have low levels of aerobic fitness (Billinger et al., 2014).  Finally, we 
must acknowledge that this study was powered for the parent study and not powered to detect the 
relationship between the functional outcome measures and estimated pre-stroke peak VO2.  This 
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study does provide data for future studies to adequately power and address scientific questions in 
this area of research. 
 
3.6. Conclusion 
There is limited information regarding CR fitness early after stroke, especially during the 
acute hospital stay.  We believe given the challenges to conducting a maximal or submaximal 
exercise test within the first few days post-stroke, a prediction equation for assessing CR fitness 
(peak VO2) was a reasonable tool to use during the acute stroke hospital stay.  Our results show 
weak, non-significant relationships between estimated pre-stroke peak VO2 early after stroke and 
our selected functional outcome measures.  When considering sex, females demonstrated a 
stronger relationship with the functional measures at discharge but only the LEFM was 
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Background:  Insulin-like growth factor-1 (IGF-1) is neuroprotective after stroke and is 
regulated by insulin-like binding protein-3 (IGFBP-3).  In healthy individuals, exercise and 
aerobic fitness (peak oxygen uptake; peak VO2) increases IGF-1 in circulation.  Understanding 
the relationship between pre-stroke aerobic fitness and IGF-1 and IGFBP-3 levels after stroke 
may provide insight into the benefits of exercise and aerobic fitness on stroke recovery. 
Objective:  The purpose of this study was to determine the relationship of IGF-1 and IGFBP-3 
to estimated pre-stroke peak VO2 in individuals with acute stroke.  We hypothesized that: 1) pre-
stroke peak VO2 would be related to IGF-1 and IGFBP-3; and 2) individuals with higher-than 
median IGF-1 levels will have higher pre-stroke peak VO2 compared to those with lower-than 
median levels.  Methods:  Fifteen individuals with acute stroke had blood sampled within 72 
hours of hospital admission.  Pre-stroke peak VO2 was estimated using a non-exercise prediction 
equation.  IGF-1 and IGFBP-3 levels were quantified using enzyme-linked immunosorbent 
assay.  Results:  Estimated pre-stroke peak VO2 was significantly related to circulating IGF-1 
levels (r = 0.60; p = .02), but not IGFBP-3.  Individuals with higher-than median IGF-1 levels 
(117.9 ng/mL) had significantly better aerobic fitness (32.3 + 7.5 mL*kg-1*min-1) than those 
with lower-than median IGF-1 (22.3 + 8.5 mL*kg-1*min-1; p = .03).  Conclusions:  Improving 
aerobic fitness prior to stroke may be beneficial by increasing baseline IGF-1 levels.  These 
results set the groundwork for future clinical trials to determine whether high IGF-1 and aerobic 




Insulin-like growth factor-1 (IGF-1) is known to be neuroprotective after middle cerebral 
artery occlusion (MCAO) in animals (Chang et al., 2011; Guan et al., 1993; Guan et al., 1996; 
Zheng et al., 2014) and may even act as a neuronal rescue agent when given through intranasal 
delivery (Guan et al., 1993; Liu et al., 2001).  When administered through intranasal delivery, 
core lesion size can be reduced up to 94% (Guan et al., 1993) while also improving functional 
status compared to vehicle controls (Zheng et al., 2014).  In humans, those with high circulating 
levels of IGF-1 early after stroke have greater survival rates and fewer impairments, tested by the 
National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS), at 3 and 
24 months post-stroke compared to those with low IGF-1 levels (Aberg et al., 2011; De Smedt et 
al., 2011; Denti et al., 2004).  This suggests that IGF-1 may also have a neuroprotective effect in 
humans.  Further, the molar ratio of IGF-1 and insulin-like growth factor binding protein-3 
(IGFBP-3), IGF-1’s primary regulatory protein, has also been observed to be related to stroke 
recovery (De Smedt et al., 2011)  Individuals with a high molar ratio of IGF-1 to IGFBP-3 
exhibited better stroke outcomes at 3 months post-stroke, indicating that having low IGFBP-3 
levels may also be beneficial to stroke recovery.  Therefore, it is important to understand what 
may influence levels of IGF-1 and IGFBP-3 in individuals with stroke. 
In healthy individuals, both circulating levels of IGF-1 and IGFBP-3 can be influenced 
by physical activity and aerobic fitness (peak oxygen consumption, peak VO2) (Cappon et al., 
1994; Eliakim et al., 1996; Morimoto et al., 2005; Nindl et al., 2011; Schwarz et al., 1996).  Prior 
work has demonstrated that people who are more physically fit have better white matter integrity 
(Tseng et al., 2013), regional brain volume (Tseng et al., 2013), and brain blood flow (Zhu et al., 
2015).  Therefore, aerobic fitness prior to a stroke may not only benefit overall brain health, but 
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also provide some level of neuroprotection via circulating IGF-1, which has been shown to 
improve stroke outcomes (Aberg et al., 2011; De Smedt et al., 2011; Denti et al., 2004).  
However, even though these studies have demonstrated that higher than median levels of 
circulating IGF-1 improve outcomes after stroke, information is lacking regarding the 
relationship of pre-stroke aerobic fitness, IGF-1, and IGFBP-3 in individuals with acute stroke. 
Assessing peak VO2 during the acute stroke hospital stay via a maximal exercise test and 
direct measurement of expired gases could be difficult if the person has unstable blood pressure, 
activity restrictions, or time constraints due to other standard of care testing.  However, one 
potential alternative method for assessing pre-stroke aerobic fitness is through the use of a non-
exercise prediction equation to estimate peak VO2.  Current literature has shown that non-
exercise equations to predict peak VO2 can be easily administered and provide useful alternatives 
to exercise testing in healthy adults and older adults (Jurca et al., 2005; Topolski et al., 2006).  
Further, we recently demonstrated the use of a non-exercise prediction equation (Jurca et al., 
2005) to estimate pre-stroke peak VO2 during the acute stroke hospital stay (Mattlage et al., 
2016).  Quick, non-exercise, prediction equations would feasibly allow for the study of pre-
stroke aerobic fitness (peak VO2) and its relationship to IGF-1 and IGFBP-3. 
Therefore, the purpose of this study was to determine the relationship of IGF-1 and 
IGFBP-3 to estimated pre-stroke aerobic fitness (peak VO2) in individuals with acute stroke.  We 
hypothesized that: 1) estimated pre-stroke peak VO2 would be significantly and positively 
correlated to IGF-1 and inversely correlated to IGFBP-3; and 2) individuals with higher than 
median circulating IGF-1 levels would have significantly higher estimated pre-stroke peak VO2 





4.3.1. Study Design 
Institution approval from the Human Subjects Committee at the University of Kansas 
(KU) Medical Center was obtained before beginning the study (HSC#00000972).  Written 




Individuals were eligible to participate in the study if they had a confirmed diagnosis of 
acute ischemic or hemorrhagic stroke, were admitted to the certified Comprehensive Stroke units 
at the KU Hospital, and were between the ages of 25 and 85 years.  Individuals were excluded 
from the study if they had: 1) acute renal failure; 2) a history of ischemic or hemorrhagic stroke, 
ischemic cardiovascular event, or coronary artery bypass graft (CABG) surgery less than 3 
months prior to their current hospital admission; and 3) congestive heart failure; or 4) severe 
peripheral artery disease. 
 
4.3.3. Estimated Pre-Stroke Peak VO2 
Pre-stroke peak VO2 was estimated using the Jurca prediction equation (Juul, 2002).  The 
Jurca prediction equation uses the following variables: sex, age, BMI, resting heart rate (rHR), 
and a self-reported measure of physical activity.  Using a questionnaire, participants or their 
surrogate decision maker were asked to estimate their average physical activity level prior to 
their stroke.  The questionnaire consists of five categories that describe varying levels of physical 
activity over the course of a typical week.  Participants (or their surrogate decision maker) were 
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asked to select one of the five categories that most accurately describes their normal activities 
during a typical week prior to being admitted to the hospital.  Each of the 5 categories is 
associated with a constant variable that is used in the prediction equation for calculation of 
estimated aerobic fitness (Level 1: 0.00 – Primarily sedentary; Level 2: 0.32 – Five days or more 
per week of light physical activity for 10 minutes or more at a time; Level 3: 1.06 – Moderate 
aerobic exercise for 20 to 60 minutes per week; Level 4: 1.76 – Moderate aerobic exercise for 1 
to 3 hours per week; Level 5: 3.03 – Moderate aerobic exercise for over 3 hours per week).Jurca 
et al., 2005  Other variables for the prediction equation (sex, age, BMI, rHR) were recorded 
immediately after consent into the study and within 72 hours of admission to the hospital.  
Resting heart rate was obtained after the participant was sitting or lying quietly for at least 30 
minutes.  Our previously published work showed that in a sample of individuals with acute 
stroke (n = 19), rHR was not significantly different between the rHR recorded during an 
outpatient, clinic visit from the electronic medical record prior to their stroke and the rHR 
recorded post-stroke (Mattlage et al., 2016).  Further, we used electronic medical record to obtain 
height and weight, measured upon admission to KU Hospital, to calculate BMI.  The equation to 
estimate peak VO2 is as follows:  METs = [Sex, F = 0; M = 1 * 2.77) – (Age in years * 0.10) – 
(BMI * 0.17) – (rHR in bmp * 0.03) + (Physical Activity Constant * 1.00) + 18.07].  METs were 
then multiplied by 3.5 in order to obtain estimated pre-stroke peak VO2 (1 MET = 3.5 mL*kg-
1*min-1). 
 
4.3.4. Quantification of Biomarkers 
Blood for quantification of IGF-1 and IGFBP-3 was obtained after an overnight fast, 
between the hours of 7:30 am and 9:00 am, and within 72 hours of stroke admission.  Ten 
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milliliters (mL) of blood from each participant was collected in a sodium heparinized tube from 
BD Biosciences (Becton, Dickinson and Company: Franklin Lakes, NJ).  Collection tubes were 
immediately put on ice and transferred to the laboratory for processing.  Within one hour of 
collection, blood samples were centrifuged to obtain plasma, aliquotted into 3, 1.5-mL 
polypropylene tubes, and frozen at -80 degrees Celsius until assaying.  New aliquots were used 
for each assay to avoid multiple freeze/thaw cycles. 
After all samples were collected, total IGF-1 (Alpco: Salem, NJ; cat#22-IGFHU-E01) 
and IGBP-3 (Alpco; Salem, NJ; cat#22-BP3HU-E01) were quantified using enzyme-linked 
immunoassays (ELISAs).  To avoid protein shock, samples were slowly thawed to room 
temperature with ice prior to assaying.  Procedures for assaying were performed exactly to the 
recommendations of the manufacturer in the manual provided with the ELISA kits. 
 
4.3.5. Data Analysis 
Pearson correlations were performed to determine the relationship of proteins (IGF-1 and 
IGFBP-3) to estimated pre-stroke peak VO2.   Median levels of IGF-1 and IGFBP-3 were 
determined using descriptive statistics.  T-tests were performed to determine the difference in 
estimated pre-stroke peak VO2 between above and below median values for both IGF-1 and 
IGFBP-3.  All statistical tests were considered significant at the alpha-level of .05 and were 
performed using IBM ® SPSS ® Statistics Version 22 (SPSS, Inc., Chicago, IL). 
 
4.4. Results 
Fifteen individuals with acute stroke (8 males, 61.1 + 10.7 years) were enrolled into the 
study and completed data collection within 72 hours of hospital admission.  Thirteen individuals 
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completed data collection within 48 hours of admission.  Table 4.1 describes the demographics 
of all participants, mean levels of IGF-1 and IGFBP-3, and the results of the non-exercise pre-
stroke peak VO2 estimation equation. 
 
Table 4.1. Participant Demographics 
Characteristics, n = 15 Number or Sample Mean (SD) Range 
Male 8 
Age (years) 61.1 (10.7) (38-75) 
Body Mass Index 30.3 (5.7) (22.8-45.7) 
National Institutes of Health Stroke Scale 8.5 (8.0) (1-22) 
Type of Stroke 
Ischemic 13 
Hemorrhagic 2 
Blood Levels (ng/mL) 
IGF-1 123.1 (57.4) (40.6-217.6) 
IGFBP-3 2220 (676) (636-2937) 
Estimated Pre-Stroke Peak VO2 (mL*kg-1*min-1) 27.0 (9.3) (8.8-45.9) 
Resting Measures 
Heart Rate (bpm) 70 (12) (53-99) 
Systolic Blood Pressure (mmHg) 145 (32) (115-222) 




Estimated pre-stroke peak VO2 was significantly and positively related to IGF-1 levels 
sampled within 72 hours of stroke (r = .60; p = .02) (Figure 4.1), but not significantly related to 
IGFBP-3 (r = -.09; p = .75).  Median level of IGF-1 and IGFBP-3 was 117.9 and 2464 ng/mL, 
respectively.  Individuals with higher than median levels of IGF-1 during acute stroke had 
significantly better estimated peak VO2 (n= 7; 32.3 + 7.5 mL*kg-1*min-1) compared to 
individuals with lower than median IGF-1 levels (n = 8; 22.3 + 8.5 mL*kg-1*min-1; p = .03) 
(Figure 4.2).  There were no significant differences in estimated peak VO2 between higher- and 
lower-than median levels of IGFBP-3. 
 

















Estimated Pre-Stroke Peak VO2 (mL*kg-1*min-1)
r = .60; p = .02 
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Figure 4.1.  Individuals with higher estimated pre-stroke peak VO2 have elevated circulating 
IGF-1 levels during acute stroke. 
Figure 4.2. Difference in Estimated Peak VO2 Between Above and Below Median IGF-1 
Levels 
 
Figure 4.2.  Individuals with above median levels of IGF-1 (>117.9 ng/mL) during acute stroke 
have significantly higher estimated pre-stroke peak VO2 (32.3 + 7.5 mL*kg-1*min-1) compared to 










































This study examined the relationship between estimated pre-stroke peak VO2, a known 
neuroprotective protein (IGF-1), and its primary regulatory protein (IGFBP-3) in individuals 
admitted to the hospital with a diagnosis of acute stroke.  To our knowledge, this is the first 
investigation to demonstrate that pre-stroke aerobic fitness (peak VO2) is related to circulating 
IGF-1 levels in people with acute stroke.  Our hypotheses were partially supported in that 
estimated pre-stroke peak VO2 was related to circulating levels of IGF-1 early after stroke, but 
not to levels of IGFBP-3.  Further, we sought to determine whether individuals with higher than 
median levels of IGF-1 would have greater aerobic fitness (peak VO2) when compared to 
individuals with lower than median levels, and found our hypothesis to be supported by our data.  
The results of this work have important implications for future studies to investigate whether 
circulating IGF-1 levels and aerobic fitness are related to functional recovery following a stroke.  
These studies would be important for further development of future rehabilitation techniques to 
improve functional recovery in individuals with stroke. 
 
4.5.1. Neuroprotection 
IGF-1 is known to be neuroprotective after stroke (Chang et al., 2011; Guan et al., 1993; 
Guan et al., 1996; Zheng et al., 2014).  In humans, individuals with higher than median levels of 
IGF-1 during the early phase of stroke have higher survival rates and less severe impairments at 
3, 6, and 24 months post-stroke compared to those with lower than median IGF-1 levels (Aberg 
et al., 2011; De Smedt et al., 2011; Denti et al., 2004).  Denti and colleagues examined IGF-1 
and IGFBP-3 levels in 85 acute stroke participants (Denti et al., 2004).  Stroke severity was 
assessed by the Barthel Index (BI) at 3 and 6 months post-stroke.  Individuals with acute stroke 
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who had IGF-1 levels less than 60 ng/mL had higher stroke severity and lower survival rates at 3 
and 6 months post-stroke (Denti et al., 2004).  DeSmedt further demonstrated the neuroprotective 
quality of baseline IGF-1 by examining IGF-1 and IGFBP-3 levels and stroke severity with the 
NIHSS and mRS (De Smedt et al., 2011).  The results showed that even when controlling for 
cardiac risk factors, such as hypertension, diabetes, atrial fibrillation, coronary artery disease, 
heart failure, smoking, and previous stroke, lower than median IGF-1 levels were related to 
increased stroke severity and lower survival rates at 3 and 6 months post-stroke when compared 
to those with higher than median levels of IGF-1 (De Smedt et al., 2011).  There were no 
associations between IGFBP-3 levels and stroke severity.  However, individuals with higher 
molar ratios of IGF-1 to IGFBP-3 had better stroke outcomes at 3 months post-stroke (De Smedt 
et al., 2011), indicating that IGFBP-3 may not directly be related to stroke recovery, but plays a 
role in regulating the availability of IGF-1, and is therefore important to consider.  The studies by 
DeSmedt and Denti have demonstrated that higher than median circulating IGF-1 improves 
outcomes after stroke and, along with IGFBP-3, is important to stroke recovery.  However, there 
is missing knowledge regarding the potential influence of factors such as pre-stroke peak VO2 
and its relationship to IGF-1 and IGFBP-3 in individuals with acute stroke. 
 
4.5.2. Aerobic Fitness 
Aerobic fitness, tested by peak aerobic capacity (peak VO2), has been directly related to 
circulating IGF-1 levels in 846 healthy men (Nindl et al., 2011).  Blood was collected in the 
morning after an overnight fast for the quantification of IGF-1.  Individuals then underwent a 
graded maximal exercise test on a cycle ergometer with direct gas analysis to obtain peak VO2.  
A repeated squats test was also performed to assess leg strength.  Individuals with higher peak 
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VO2 exhibited higher levels of circulating baseline IGF-1.  Further, better aerobic fitness was 
associated with increased performance on the repeated squats test, indicating a greater functional 
performance in the lower extremities (Nindl et al., 2011).  Nindl’s study in healthy men could 
potentially have very large implications for individuals post-stroke.  However, the relationship of 
exercise performance, specifically, aerobic fitness, to IGF-1 levels had not yet been tested in 
individuals with stroke prior to the current study, but gives important insight for which future 
studies could be based. 
Testing aerobic fitness in individuals with stroke can be extremely difficult due to neuro-
motor limitations in the lower extremities.  In the acute setting, it is particularly challenging 
because of various factors such as time constraints for standard of care diagnostic assessments, a 
lack of trained professionals and specialized equipment, and extreme fatigue of the participant.  
However, our previous work displays feasibility of the use of a non-exercise prediction equation 
to estimate pre-stroke peak VO2 in individuals admitted to the hospital with a diagnosis of acute 
stroke (Mattlage et al., 2016).  Our work showed that estimated pre-stroke peak VO2 was easily 
administered.  The results of the current study corroborates these findings, but also shows that 
this easily-administered tool to estimate pre-stroke aerobic fitness may also influence IGF-1 
levels in individuals with acute stroke. 
The results of the current study are novel and important as we found a strong and 
significant relationship between pre-stroke aerobic fitness (peak VO2) and IGF-1.  Although this 
requires further exploration, it is plausible that pre-stroke aerobic fitness may have a potential 
benefit following stroke.  In healthy men, those with higher peak VO2 and greater lower 
extremity functional ability, had higher levels of circulating baseline IGF-1 (Nindl et al., 2011).  
In our study, we also report that individuals with higher estimated pre-stroke peak VO2 have 
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above median levels of IGF-1 when compared to individuals with lower than median levels of 
IGF-1.  However, the current study does not answer questions regarding IGF-1 levels and 
functional performance of the lower extremity, but provides strong rationale for further 
investigation.  Further, we did not observe a significant relationship between estimated pre-
stroke peak VO2 and circulating IGFBP-3 levels.  The lack of the hypothesized relationship 
could be due to many factors.  In the study by DeSmedt, IGFBP-3 was not directly related to 
stroke outcomes, but the ratio of IGF-1 to IGFBP-3 was (De Smedt et al., 2011).  It is possible 
that IGFBP-3 can be influenced by exercise short term, but baseline levels may not be directly 
related to aerobic fitness.  Further, changes in IGFBP-3 circulating levels may depend on the 
type or duration of exercise (Chadan et al., 1999). 
 
4.5.3. Limitations 
We must acknowledge that the participants, or their surrogate decision maker, may report 
higher or lower activity levels, and thereby, influence the pre-stroke peak VO2 estimation.  From 
our prior work using the Jurca non-exercise estimation equation in acute stroke (Mattlage et al., 
2016) and others using the equation in community-dwelling adults and older adults with several 
cardiovascular risk factors (Jurca et al., 2005; Mailey et al., 2010) we believe this is a feasible 
and safe alternative in comparison to conducting a maximal exercise test on individuals who are 
within 72 hours of stroke 
Further, the current study was limited by a small sample size and the results should be 
interpreted with caution.  Despite this, we believe the results of our study give rise to further 
questions regarding pre-stroke aerobic fitness, IGF-1, and functional recovery.  Future work 
should address whether pre-stroke aerobic fitness and IGF-1 in acute stroke influence functional 
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recovery and stroke outcomes.  Finally, blood was sampled, on average, within 48 hours of 
stroke admission.  The sampling window used was more narrow than one study which sampled 
blood anywhere between 1 and 10 days post-stroke (Aberg et al., 2011).  Although we sampled 
blood within at most 72 hours, our time window for sampling blood was wider than previous 
studies examining IGF-1 and stroke outcomes (De Smedt et al., 2011; Denti et al., 2004).  
However, we believe that this would have minimal effect on our study as there is no suggested 
optimal time to obtain blood for the quantification of IGF-1 and IGFBP-3. 
 
4.6. Conclusion 
This study investigated the relationship between IGF-1 and IGFBP-3 levels and pre-
stroke estimated peak VO2 in individuals with acute stroke.  We hypothesized that 1) pre-stroke 
estimated peak VO2 would be positively and significantly related to IGF-1 and negatively related 
to IGFBP-3; and 2) individuals with higher than median circulating IGF-1 levels would have 
significantly better estimated pre-stroke peak VO2 compared to individuals with lower than 
median levels of IGF-1.  Our results partially supported this hypothesis in that we observed a 
significant, positive relationship between pre-stroke peak VO2 and circulating IGF-1 levels, but a 
non-significant relationship with IGFBP-3.  Further, our second hypothesis was supported and 
demonstrated that individuals with higher than median levels of IGF-1 had higher pre-stroke 
estimated peak VO2, while individuals with lower than median levels of IGF-1 had a lower pre-
stroke estimated peak VO2.  The results of this study are novel and significant to the field in that 
they provide support for future studies for examining how aerobic fitness, IGF-1, and IGFBP-3 
levels are related to recovery and physical function after stroke.   
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5. CHAPTER 5. DECREASE IN IGF-1 AND IGF-1 
RATIO DURING THE FIRST WEEK OF STROKE IS 
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Background:  High insulin-like growth factor-1 (IGF-1) levels, measured once during acute 
stroke, is associated with greater survival rates and lower stroke severity.  However, information 
is lacking regarding how IGF-1 availability, determined by IGF-1’s ratio to insulin-like growth 
factor binding protein-3 (IGFBP-3), relates to recovery and how the response of IGF-1 during 
the first week of stroke relates to stroke outcomes.  The purpose of this study was to determine: 
1) the relationship between percent-change in IGF-1 and IGF-1 ratio during the first week of 
stroke and stroke outcomes; and 2) the difference in percent-change in IGF-1 and IGF-1 ratio in 
individuals who discharged home and individuals who discharged to inpatient facilities.  
Methods:  IGF-1 and IGFBP-3 were quantified from blood sampled twice (<72 hours of 
admission; 1-week post-stroke) in fifteen individuals with acute stroke.  Length of stay (LOS), 
modified Rankin Scale (mRS) at one-month, and discharge destination were obtained from 
electronic medical records.  Results:  Percent-change in IGF-1 ratio was related to LOS (r=.54; 
p=.04).  mRS (n=10) was related to percent-change in IGF-1 (r=.90; p<.001) and IGF-1 ratio 
(r=.75 p=.01).  Those who went home (n=7) had decreases in IGF-1 levels (-24+25%) and IGF-1 
ratio (-36+50%), while those who went to inpatient facilities (n=8) had increases in IGF-1 levels 
(37+46%) and IGF-1 ratio (30+40%). These differences were significant (IGF-1: p=.008; IGF-1 
ratio p=.01).  Discussion:  Our findings suggest that a decrease in IGF-1 and IGF-1 ratio during 
the first week of stroke is associated with favorable outcomes: shorter LOS, lower mRS at one-




In humans, low levels of insulin-like growth factor-1 (IGF-1) are associated with stroke 
risk factors such as ischemic heart disease, myocardial infarction, diabetes, and coronary artery 
disease, while high insulin-like growth factor binding protein-3 (IGFBP-3) levels are associated 
with ischemic heart disease (Juul, 2002; Rajpathak et al., 2012; Vasan et al., 2003).  Moreover, 
low IGF-1 has been directly correlated to greater stroke risk in humans (Denti et al., 2004; Dong 
et al., 2014; Johnsen, 2005).  Higher levels of IGF-1 with simultaneously low levels of IGFBP-3 
allow for greater amounts of free, unbound IGF-1 in circulation, which, in turn, elicits IGF-1 to 
trigger cascades in neuroprotective pathways.  In individuals with stroke, many studies have 
agreed that high baseline levels of IGF-1 in circulation, measured once within the first few weeks 
of stroke, are linked to lower stroke severity and greater rates of survival at one-month post 
stroke (Aberg et al., 2011; Bondanelli et al., 2006; De Smedt et al., 2011; Denti et al., 2004; 
Ebinger et al., 2015; Tang et al., 2014). 
While some studies have examined IGFBP-3 after stroke (De Smedt et al., 2011; Ebinger 
et al., 2015), there still remains a disparity in knowledge regarding the relationship of IGF-1 ratio 
(IGF-1:IGFBP-3) to stroke recovery.  Because IGF-1 ratio reflects the amount of free IGF-1 
available to reach its receptor, it is important to consider.  Furthermore, while high baseline IGF-
1 levels have been shown to be related to positive outcomes, the response of IGF-1 during the 
first week is not yet known and may provide further insight into IGF-1’s potential 
neuroprotective benefit to stroke outcomes. 
Outcomes such as length of stay (LOS) in the hospital, modified Rankin Scale (mRS), 
and discharge destination have been used in individuals with stroke to evaluate the relationship 
between easily-assessable and short-term outcomes, functional status, and other measures of 
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stroke recovery.  One study showed that motor recovery was improved after the first year of 
stroke in people with a shorter LOS during their first hospital admission for stroke 
(Kuptniratsaikul et al., 2016).  LOS was also negatively related to improvements on the 
Functional Independence Measure (FIM) (Ifejika et al., 2015).  Moreover, discharge destination 
has been associated acute FIM measures, mortality rates, and global disability at 3 months post-
stroke (Bekelis et al., 2016; Roberts et al., 2015; Zhang et al., 2015).  However, the relationship 
between these stroke outcomes and IGF-1 and IGF-1 are yet to be determined. 
Therefore, the purpose of this study was to: 1) determine the relationship between percent 
change in IGF-1 and IGF-1 ratio during the first week of stroke and stroke outcomes (LOS and 
mRS at one-month post-stroke); and 2) determine the difference in percent change in IGF-1 and 
IGF-1 ratio in discharge destination (i.e. individuals who discharged home vs. individuals who 
discharged to inpatient facilities).  We hypothesized that: 1) an increase in IGF-1 and IGF-1 ratio 
during the first week of stroke would be associated with fewer days spent in the hospital (LOS) 
and more functional independence at one month post-stroke (mRS); and 2) individuals who 
discharge home will have a significantly greater percent change in IGF-1 and IGF-1 ratio 





5.3.1. Study Design 
This prospective study used a sample of convenience from University of Kansas (KU) 
Hospital’s certified Comprehensive Stroke neuro-progressive and neuro-intensive care units.  
Institution approval from the Human Subjects Committee at KU Medical Center was obtained 
before commencement of the study.  Written informed consent was obtained by the participant or 
their surrogate decision maker prior to study participation. 
 
5.3.2. Participants 
Individuals with stroke were eligible for participation if they were admitted to KU 
Hospital with a diagnosis of acute ischemic or hemorrhagic stroke and were between 25 and 85 
years of age.  Individuals were excluded from the study if they: 1) had acute renal failure; 2) had 
a history of ischemic or hemorrhagic stroke, ischemic cardiovascular event, or coronary artery 
bypass graft (CABG) surgery less than 3 months prior to their current hospital admission for 
stroke; 3) had a diagnosis of congestive heart failure; or 4) had severe peripheral artery disease.  
Demographics of enrolled participants can be found in Table 5.1.   
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Table 5.1. Participant Demographics 
Characteristics, n = 15 Number or Sample Mean (SD) Range 
Male 8 
Age (years) 61.1 (10.7) (38-75) 
Body Mass Index 30.3 (5.7) (22.8-45.7) 
National Institutes of Health Stroke Scale 8.5 (8.0) (1-22) 
Modified Rankin Scale 2 (1.4) (1-5) 
HbA1C 5.9 (1.3) (5.1-9.8) 
Race/Ethnicity 
White/Caucasian 13 









Type of Stroke 
Ischemic 13 
Hemorrhagic 2 




Table 5.1. Participant Demographics (Continued) 
Characteristics, n = 15 Number or Sample Mean (SD) Range 
Comorbidities 
Smoker 4 









5.3.3. General Methods 
Individuals were enrolled into the study and had baseline blood samples collected within 
72 hours of hospital admission for acute stroke.  Blood at baseline was sampled between 7:30 
and 9:00 am after an overnight fast.  One week following stroke, blood was sampled again 
during similar hours, after an overnight fast.  Demographic data (age, height, weight, and body 
mass index), results of laboratory chemistry testing on admission (hemoglobin A1c), enzyme 
analysis of liver function on admission (aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT)), and other stroke related information (admitting National Institutes of 
Health Stroke Score (NIHSS) and lesion volume) were obtained from each participants’ 
electronic medical record (EMR). 
 
5.3.4. Stroke Outcomes 
Calendar days spent in the hospital (LOS), discharge destination (i.e. home vs. inpatient 
facility), and functional independence at 1-month post-stroke, assessed by the mRS, was also 
obtained from each participant’s EMR. 
 
5.3.5. Quantification of Biomarkers 
One, ten-milliliter (mL) sodium heparinized tube was used for obtaining blood from each 
participant.  Collection tubes were immediately put on ice and transferred to the laboratory for 
processing.  Within an hour of collection, blood samples were centrifuged to separate and obtain 
plasma.  Plasma was then aliquotted into 3, 1.5-mL polypropylene PP tubes and stored frozen at 
-80 degrees Celsius until assaying.  Freeze/thaw cycles were limited by using a new, once-
thawed aliquot for each assay. 
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After all samples were obtained from each participant, enzyme-linked immunosorbent 
assays (ELISAs) were used to quantify total circulating IGF-1 (Alpco: Salem, NJ; cat#22-
IGFHU-E01) and IGFBP-3 (Alpco; Salem, NJ; cat#22-BP3HU-E01).  All samples from one 
participant were quantified on the same ELISA plate.  Samples were slowly thawed to room 
temperate using ice before assaying in order to avoid protein-shock.  Procedures were performed 
exactly to the manufacturer’s recommendations.  Six standards were made in order to create a 
standard curve. Two internal controls of known concentrations were provided by each kit.  
Observed values of both the standard curve and the known concentrations were determined to be 
within acceptable ranges before interpreting the data. 
 
5.3.6. Statistical Analysis 
Baseline demographics were calculated using descriptive statistics.  IGF-1 ratio (the ratio 
of IGF-1 to IGFBP-3) was calculated by dividing the amount of total circulating IGF-1 by the 
amount of total circulating IGFBP-3.  Percent change in IGF-1 and IGF-1 ratio during the first 
week of stroke was calculated as: Percent Change = [(1 week – baseline)/(baseline)*100].  For 
aim 1 of the study, Pearson correlations were performed to determine the relationship between 
percent change in IGF-1 and IGF-1 ratio and stroke outcomes (LOS and mRS).  For the second 
aim of the study, independent t-tests were performed to determine the difference in percent 
change in IGF-1 and IGF-1 ratio between those who discharged home and those who discharged 
to an inpatient facility.  All analyses were performed using IBM® SPSS® Statistics Version 22 






Fifteen individuals (8 males, 61.1 + 10.7 years) were enrolled into the study and started 
data collection within 72 hours of hospital admission.  Table 5.2 outlines IGF-1 and IGF-1 ratio 
levels at each time point and percent changes in IGF-1 and IGF-1 ratio from baseline to 1-week 
post-stroke.  Additionally, since the majority of circulating IGF-1 is synthesized in the liver, 
enzymes to assess liver function (AST and ALT) were analyzed.  Liver enzymes, AST and ALT, 
were within normal ranges for all subjects (Table 5.3). 
 
Table 5.2. Blood Levels 
 Visit 1 Visit 2 % Change 
n = 15 (<72 Hours) (1 Week) 
IGF-1 (ng/mL) 123 (57) 129 (89) 8.5 (47.7) 
IGFBP-3 (ng/mL) 2220 (675) 2536 (589) 41.2 (109.9) 




Table 5.3.  Characteristics of Individuals Who Discharged Home vs. Individuals Who 
Discharged to Inpatient Facilities 
n = 15 Home Inpatient p-
value 
Age (years) 62 (10) 60 (11) .75 
Body Mass Index 28 (4) 32 (6) .17 
Lesion Volume (cm3) 2 (3) 25 (29) .06 
Length of Stay (days) 6(5) 10 (6) .27 
Baseline IGF-1 (ng/mL) 145 (48) 103 (60) .17 
1 Week IGF-1 (ng/mL) 112 (59) 144 (110) .51 
Baseline IGFBP-3 (ng/mL) 2036 (906) 2380 (380) .38 
1 Week IGFBP-3 (ng/mL) 2610 (829) 2471 (308) .67 
Baseline IGF-1 Ratio .04 (.02) .1 (.08) .11 
1 Week IGF-1 Ratio .01 (.03) .05 (.01) .38 
Aspartate Aminotransferase (U/L) 14 (4) 19 (8) .68 




5.4.1. Length of Stay 
Our results showed that percent change in IGF-1 ratio was significantly related to LOS (r 
= .54; p = .04) (Figure 5.1), suggesting that as the percent change in IGF-1 ratio during the first 
week of stroke increases, individuals are staying in the hospital longer.  However, percent 
change in IGF-1 alone was not significantly related to LOS. 
 
Figure 5.1.  Relationship of Percent Change in IGF-1 Ratio and Length of Stay 
 
Figure 5.1  Individuals with a higher percent change in IGF-1 Ratio during the first week of 
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5.4.2. Modified Rankin Scale  
For individuals with a mRS at 1 month post-stroke (n = 10), our results showed that there 
was a significant relationship between mRS and percent change in both IGF-1 (r = .901; p < 
.001) (Figure 5.2) and IGF-1 ratio (r = .750; p = .012) (Figure 5.3) during the first week of 
stroke.  As individuals had larger increases in IGF-1 and IGF-1 ratio during the first week, they 
also had greater scores on the mRS (lower functional independence) at one month post-stroke.  
These results corroborate the observation of the relationship of IGF-1 ratio to LOS and provide 
additional evidence to suggest that a decrease in circulating IGF-1 and IGF-1 ratio is associated 
with positive, or more favorable, outcomes. 
 
Figure 5.2. Correlation Between Percent Change in IGF-1 and mRS at One Month 
 
Figure 5.2  Individuals with a higher percent change in IGF-1 during the first week of have a 
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Figure 5.3.  Correlation Between Percent Change in IGF-1 Ratio and mRS at One Month 
 
Figure 5.3  Individuals with a higher percent change in IGF-1 Ratio during the first week of 
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5.4.3. Discharge Destination 
Finally, those who went home (n = 7) had negative percent changes (decreases) in IGF-1 
(-24 + 25%) (Figure 5.4) and IGF-1 ratio (-36 + 50%) (Figure 5.5) during the first week of 
stroke.  Contrarily, those who went to inpatient facilities (n = 8) had positive percent changes 
(increases) in IGF-1 (37 + 46%) and IGF-1 ratio (30 + 40%) during the first week of stroke.  The 
difference in percent change of IGF-1 (p = .008) and IGF-1 ratio (p = .014) between discharge 
destinations (home vs. inpatient) was significant. 
Baseline demographics were not significantly different between individuals who went 
home and individuals who discharged to impatient facilities (Table 5.3).  Further, because both 
groups did not have a significant difference in either liver enzymes, we cannot contribute the 




Figure 5.4.  Change in IGF-1 and Discharge Destination 
 
Figure 5.4  Individuals who discharged home from the hospital had decreases in IGF-1 levels 
during the first week of stroke, while individuals who discharged to inpatient facilities had 
increases in IGF-1 levels (p = .008).  
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Figure 5.5.  Change in IGF-1 Ratio and Discharge Destination 
 
Figure 5.5  Individuals who discharged home from the hospital had decreases in IGF-1 Ratio 
during the first week of stroke, while individuals who discharged to inpatient facilities had 




Our hypothesis that an increase in IGF-1 and IGF-1 ratio during the first week of stroke 
would result in fewer days spent in the hospital, lower mRS scores (less functional 
independence) at one month, and discharging home was not supported.  In fact, our results 
showed the opposite in some measures of IGF-1: a decrease in IGF-1 and/or IGF-1 ratio during 
the first week of stroke was related to positive outcomes (i.e. discharging home and lower mRS 
at one month).  Although the results of the current study were not as expected, the findings have 
important implications for stroke recovery in humans and raise additional questions for which 
future work should be based. 
 
5.5.1. Insulin-Like Growth Factor-1 
In humans, studies have been performed for which their results indicate that high baseline 
measurements of IGF-1 are related to better stroke recovery and greater survival rates.  Aberg 
and colleagues measured IGF-1 levels from the serum of stroke patients between 1 and 19 days 
post-stroke (Aberg et al., 2011).  Baseline serum IGF-1 levels in individuals with acute stroke 
were significantly associated with improvements in the mRS and Scandinavian Stroke Scale 
tested at 3 and 24 months post stroke.  However, the widespread variation of sampling may have 
impeded their ability to draw conclusions.  Individuals who had their blood sampled from Day 0-
2 showed statistically different IGF-1 levels compared to those who had their blood sampled on 
Days 9-19.  This indicates that IGF-1 levels during the first two weeks of stroke are not stable 
(show either significant decreases or increases) and that regulation of IGF-1 has the potential to 
differ from person to person.  No studies have examined how this response, during the first few 
weeks of stroke, relates to recovery or stroke outcomes.  The current study seeks to fill this gap 
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and provides novel, preliminary evidence to suggest that decreases in IGF-1 and IGF-1 ratio 
during the first week of stroke may be beneficial to recovery. 
Experimental studies may provide insight into why the results of the current study were 
opposite to our original hypotheses.  Chang and colleagues showed important evidence of IGF-
1’s ability to exert neuroprotective benefits and that during this time, brain levels of IGF-1 
increase while peripheral levels decrease, suggesting uptake of IGF-1 into the brain from 
circulation (Chang et al., 2011).  IGF-1 levels were measured 14 days after MCAO from the 
affected motor cortex, striatum, and plasma.  IGF-1 was significantly decreased in the plasma, 
while significantly increased in the motor cortex and striatum.  Although we are not able to 
measure IGF-1 in the brain of humans pre-mortem, the findings of Chang’s study are important 
for the interpretation for the current study in that the decreases in IGF-1 seen in the periphery in 
humans may underlie increases in IGF-1 in the brain.  It is important for future studies in acute 
stroke to examine the change in both peripheral circulating IGF-1 and CSF levels of IGF-1 in 
order to determine whether individuals who have decreases in IGF-1 during the first week are 
more efficient at IGF-1 uptake into the CSF and brain and whether these measures are related to 
functional stroke outcomes. 
 
5.5.2. Stroke Outcomes 
Many studies have used stroke outcomes such as LOS in the hospital, mRS, and 
discharge destination to assess recovery.  These outcomes are extremely easy to collect and are 
many times automatically tracked and calculated by electronic medical record systems.  LOS and 
discharge destination can be used as markers of recovery in the investigations of meaningful 
relationships to other recovery outcomes and neuroprotective agents. 
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A study performed by Kuptniratsaikul and colleagues examined motor recovery in 192 
individuals with stroke across nine hospitals (Kuptniratsaikul et al., 2016).  Motor recovery at 6 
and 12 months after stroke was assessed by the Brunnstrom motor recovery stages (BMRS).  The 
BMRS is broken into 6 stages of recovery with each level (1-6) describing progressive 
improvements in movement patterns in the hand, arm and leg, separately.  Their results showed 
that improvements in the BMRS were associated with a shorter length of stay (Kuptniratsaikul et 
al., 2016).  Another study, which investigated 481 individuals with acute stroke, determined the 
relationship between Functional Independence Measure (FIM) scores on admission and 
discharge destination (Roberts et al., 2015).  They observed that individuals who discharged to 
the community, rather than to inpatient rehabilitation, had significantly better FIM scores upon 
admission (Roberts et al., 2015).  Other studies have shown significant relationships between 
discharge destination and LOS with global disability at three months and having a fall during 
hospitalization (Wong et al., 2015; Zhang et al., 2015). 
These studies indicate that easily obtainable outcome measures such as LOS and 
discharge destination can give valuable information into stroke recovery and physical function in 
individuals with stroke.  However, their relationship to the response of IGF-1 and IGF-1 ratio 
after stroke has been understudied in humans.  Our results were novel in that we showed that 
decreases in IGF-1 and IGF-1 were associated with a shorter LOS, better mRS at one-month 
post-stroke, and discharging home.  Large clinical trials examining the relationship between the 
response of IGF-1 and IGF-1 ratio during the first week and objective functional outcomes can 






This study provides novel evidence regarding the potential importance of the percent 
change in IGF-1 and IGF-1 ratio during the first week of stroke in understanding recovery.  
However, a limitation of the current study is that circulating concentrations of IGF-1 were not 
supplemented with the levels of IGF-1 in the cerebral spinal fluid (CSF).  Quantifying IGF-1 and 
IGF-1 ratio in the CSF can provide information regarding levels in the brain.  IGF-1 is known to 
cross the blood-brain barrier (BBB) and measuring it in CSF can be beneficial.  An experimental 
study showed evidence of IGF-1 crossing the BBB by inducing a middle cerebral artery 
occlusion (MCAO) in rats and administering radio-labeled IGF-1 into periphery immediately 
after.  Within 30 minutes of IGF-1 administration, the majority of IGF-1 proteins were seen to be 
associated with neurons of the infarcted hemisphere (Liu et al., 2001). 
Another limitation of the current study is the small sample size and lack of objective 
functional measurements.  Larger clinical trials need to be performed in order to corroborate 
these findings, while also assessing functional ambulation and performance of activities of daily 
living.  Although used in previous literature, the outcomes in this study (LOS, mRS, and 
discharge destination) limit our ability to understand how percent change in IGF-1 and IGF-1 
ratio relate to objective measurements of functional recovery such as walking endurance and 
walking speed.  Finally, other factors, unaccounted for in the current study, may influence the 
outcome of LOS and discharge destination.  One study suggests that decisions of discharge 
destinations may be influenced by not only the condition of the individual with stroke, but also 
by social, economic, and policy factors (Johnson et al., 2015).  However, another suggests that 
discharge destination is among the strongest of variables to predict global disability at 3 months 
(Zhang et al., 2015).  The current study provides support in favor of undergoing larger, clinical 
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trials that use objective, measurable assessments of physical function to assess the potential 
benefits of IGF-1 and IGF-1 ratio. 
 
5.6. Conclusions 
Despite the suggestion of current literature regarding high baseline levels of IGF-1, our 
novel findings suggest that a decrease in IGF-1 and IGF-1 ratio during the first week of stroke 
may be related to positive, or more favorable, outcomes (i.e. shorter LOS, discharging home vs 
inpatient facilities, and improved functional independence at one-month post-stroke).  When 
studying IGF-1 and its relationship to stroke recovery in humans, it may be important to consider 
multiple measurements of IGF-1 instead of single, baseline time points.  Moreover, multiple 
measurements of IGF-1 ratio may also deepen our understanding of how IGF-1 is regulated after 
stroke and how this relates to functional recovery.  The percent change in IGF-1 and IGF-1 ratio 
may be a meaningful biomarker of stroke recovery at one month.  Further work is warranted in a 
larger clinical trial and in experimental models to determine why decreases in IGF-1 and IGF-1 
ratio are beneficial and their relationship to objective measurements of function during the 
recovery of stroke.  
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Discussion and Conclusions  
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6.1. Summary of Findings 
The research and data presented in this dissertation was undertaken with the goal of 
understanding physical and physiological characteristics of the acute phase of stroke recovery.  
Stroke rehabilitation and recovery during the acute stage is an understudied area of research, 
specifically in the areas of physical activity, aerobic fitness, and insulin-like growth factor 1 
(IGF-1), a known neuronal rescue agent.  Our results show that individuals after stroke are 
extremely sedentary during their acute hospital stay and that increased sedentary time may be 
related to decreased function after stroke.  Further, we demonstrated that we could assess pre-
stroke aerobic fitness within 48 hours of hospital admission using a previously established and 
clinically feasible tool to predict aerobic fitness.  This was an important finding and it has 
clinical utility for healthcare professionals working with individuals after stroke.  We found that 
pre-stroke aerobic fitness was positively correlated with circulating levels of IGF-1.  These 
results provide additional information regarding the benefits of exercise and aerobic fitness on 
stroke recovery and support that improving aerobic fitness prior to stroke may be beneficial 
through increases in baseline IGF-1.  Finally, we showed that decreased circulating IGF-1 during 
the first week of stroke may be related to positive outcomes after stroke (i.e. discharging home 
vs. an inpatient facility and more independence in activities 1-month post stroke).  However, the 
interplay between physical activity, aerobic fitness, and IGF-1 and how these factors are related 
to objective, functional outcomes after stroke remains unclear.  The current set of experiments 
has provided the framework for future research in this area.  This chapter summarizes the 
findings presented in this body of work and concludes with important clinical implications, 
limitations of our investigations, and directions for which future studies should be based. 
6.1.1. Chapter 2. Use of Accelerometers to Examine Sedentary Time on an Acute Stroke Unit 
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The amount of physical activity performed by individuals with stroke has been quantified 
and observed previously in community-dwelling individuals with chronic stroke.  Behavioral 
mapping for physical activity has been conducted during the acute and subacute stage of stroke 
recovery.  However, no studies have objectively quantified physical activity, specifically, using 
accelerometers during their initial hospital stay.  Using accelerometers provides greater 
understanding of how sedentary time very early after stroke may affect function and recovery 
post-stroke.  Therefore, we undertook the study of quantitatively assessing sedentary time using 
tri-axial accelerometers during the first several days of stroke in the acute hospital setting.  We 
then determined whether sedentary time was related to functional performance at discharge from 
the hospital. 
Our investigation of 32 individuals showed that individuals with acute stroke spent a large 
majority of time sedentary during their hospital stay.  Sedentary time was positively related to 
the Physical Performance Test, even when controlling for baseline performance, which suggests 
that individuals who spent more hospital time sedentary performed worse on functional tasks 
prior to discharge, regardless of their performance at baseline.  These results demonstrate that 
people recovering from stroke spend most of their hospital stay sedentary.  Our results may have 
important implications for stroke recovery. 
 
6.1.2. Chapter 3. Use of a Non-Exercise Estimate for Pre-Stroke Peak VO2 during the Acute 
Stroke Hospital Stay 
Previous literature shows that aerobic fitness, or peak VO2, is diminished in individuals 
with subacute and chronic stroke.  However, information is lacking regarding peak VO2 levels in 
individuals very early after stroke.  This is partly due to the difficultly in measuring peak VO2 in 
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these individuals.  Performing maximal exercise tests during this sensitive time is infeasible due 
to a myriad of reasons such as time constraints, motor limitations, and lack of resources (i.e. 
expensive equipment, trained personnel, and medical oversight).  However, feasible-to-use, non-
exercise estimations of aerobic fitness very early after stroke may give way to new and 
groundbreaking insight into stroke recovery.  Chapter 2 focused on using a previously validated 
non-exercise estimation equation to predict pre-stroke peak VO2 in individuals with acute stroke 
during their hospital stay.  Further, we set out to examine whether estimated pre-stroke peak VO2 
was related to function at hospital discharge. 
Our results suggest that the non-exercise estimation of pre-stroke peak VO2 is easily 
administered within 48 hours of hospital admission in individuals with acute stroke.  Analysis of 
the relationship between estimated pre-stroke peak VO2 and functional performance at discharge 
revealed no significant relationships when considering the total sample.  However, when 
stratifying the sample by gender, significant relationships were observed in females between 
estimated pre-stroke peak VO2 and the Fugl-Meyer Assessment of lower extremity motor 
function.  Females with higher aerobic fitness prior to stroke exhibited better motor function of 
the lower extremities at discharge from the hospital.  However, no significant relationships were 
observed for men.  This could be due to a poor prediction of aerobic fitness in men because of 
over estimations of self-reported physical activity levels.  Therefore, estimations of pre-stroke 
peak VO2 are feasible to use in individuals during the acute hospital setting.  However, the 
association between pre-stroke aerobic fitness and functional recovery remains unclear.  
Nonetheless, the results of this investigation provide important information for future studies to 
characterize fitness prior to stroke and how it may relate to objective measures of physical 
function during stroke recovery. 
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6.1.3. Chapter 4. Estimated Pre-Stroke Peak VO2 is Related to Circulating IGF-1 Levels during 
Acute Stroke 
Current literature suggests that IGF-1 is neuroprotective after stroke, such that higher levels 
of IGF-1 early after stroke are associated with positive outcomes (i.e. greater survival rates and 
greater independence).  Further, in healthy individuals, IGF-1 levels can be influenced by 
physical activity and aerobic fitness.  Therefore, to further understand the relationship of aerobic 
fitness and potential mechanisms of neuroprotection during stroke recovery, we sought to 
examine a known neuronal rescue agent, IGF-1, and its relationship to estimated pre-stroke peak 
VO2 levels in individuals with acute stroke.  Individuals completed a questionnaire which 
estimated pre-stroke peak VO2 and had blood drawn within 72 hours of hospital admission for 
determination of IGF-1 levels. 
Our results indicate that, in 15 individuals with acute stroke, estimated pre-stroke peak VO2 
is significantly related to circulating IGF-1 levels obtained within 72 hours of hospital admission.  
Further, individuals with higher than median IGF-1 levels possessed significantly better aerobic 
fitness prior to their stroke.  These results indicate that improving aerobic fitness prior to stroke 
may be beneficial and provide neuroprotection by increasing baseline IGF-1 levels.  These 
results inspire questions for future studies to investigate whether IGF-1 and aerobic fitness 
interact to protect and/or maintain physical function during stroke recovery. 
 
6.1.4. Chapter 5. Change in IGF-1 Levels and the Ratio of IGF-1 to IGFBP-3 during the First 
Week of Stroke is Related to Stroke Outcomes 
Chapter 6 gives evidence to suggest that aerobic fitness prior to stroke may provide 
neuroprotection through IGF-1 during post-stroke recovery.  Current literature also describes 
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IGF-1 as having neuronal rescue abilities.  Both in animal models and in humans, IGF-1 has 
provided neuroprotection to individuals with stroke.  However, in humans, studies have 
primarily been employed using questionnaires and broad assessments of outcomes of stroke.  
Many studies have seen that individuals with high IGF-1 soon after stroke have a greater chance 
at survival and more independence 3 months later.  However, these studies may have provided a 
limited understand of IGF-1’s neuroprotective qualities by not considering how the response of 
IGF-1 during the first weeks of stroke is important and by only using general questionnaires to 
assess outcomes.  Therefore, Chapter 5 aimed to characterize the response of IGF-1 during the 
first week of stroke and how it may be related to outcomes (i.e. discharge placement and 
independence). 
Individuals with decreases in IGF-1 during the first week of stroke had more desirable 
outcomes compared to individuals with increases in IGF-1.  The same is also true for the ratio of 
IGF-1 and IGFBP-3.  Individuals with increases in IGF-1 and IGF-1 ratio (defined as IGF-
1:IGFBP-3) during the first week had a longer length of stay in the hospital, had less 
independence and greater stroke severity at one month post-stroke, and went to inpatient 
facilities instead of directly home when discharged from the hospital.  Baseline IGF-1 and IGF-1 
ratio were not related to any outcomes and were not significantly different between those who 
went home or those who went to inpatient facilities.  While other studies have shown that high 
baseline levels of IGf-1 are related to positive outcomes, these results may provide preliminary 
evidence that the change in IGF-1 and IGF-1 ratio during the first week of stroke are also 
important to recovery. Further work should be done to investigate the relationship between 




6.2. Sedentary Time, Estimated Aerobic Fitness, and IGF-1 Levels in Individuals with 
Acute Stroke 
6.2.1. Sample and Methods 
A total of 44 individuals admitted to the hospital with a diagnosis of acute stroke were used 
for the analyses presented in these investigations.  Individuals were recruited 24-72 hours of 
admission to the neuro-progressive or neuro-intensive care units of University of Kansas 
Hospital.  All individuals signed institutionally approved informed consent forms prior to the 
initiation of data collection. 
Chapters 2 and 3 focused on the objective quantification of sedentary time, estimation of 
pre-stroke aerobic fitness, and their relationship to functional recovery.  Individuals were fitted 
with tri-axial accelerometers, which they wore on their ankles until discharge from the hospital, 
or for a maximum of 4 days.  Additionally, individuals completed questionnaires to assess pre-
stroke physical activity (Rapid Assessment of Physical Activity; RAPA) and aerobic fitness 
(non-exercise estimate of peak VO2).  Finally, individuals completed the following objective 
assessments of functional performance: Fugl-Meyer Assessment of lower extremity motor 
function, 6 Minute Walk Test, Timed-Up and Go with dual cognitive task, and the Physical 
Performance Test.  Functional assessments were completed immediately after enrollment and 
prior to discharges (or 4 days following baseline assessments). 
In Chapters 4 and 5, blood draws were performed by hospital staff or study team members, 
in the morning, and under fasting conditions.  Within one hour of collection, samples were 
centrifuged at 4°C, and 1,900 rcf for 15 minutes to separate and obtain plasma.  Each plasma 
sample was aliquoted into 3-1.5 mL microcentrifuge polypropylene tubes and stored at -80°C 
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until assaying.  Finally, after all samples were collected, IGF-1 and IGFBP-3 were quantified 
using ELISA kits from ALPCO® Diagnostics (Salem, NH). 
 
6.2.2. Statistical Analysis 
Pearson’s correlations were performed to assess the relationship between two variables.  In 
some cases a partial correlation was used to control for a confounding variable.  T-tests were 
performed when assessing between group differences.  Type 1 error (p-value) was always set at 
0.05.  IBM ® SPSS ® Statistics Version 22 (SPSS, Inc., Chicago, IL) was used for all statistical 
analyses. 
 
6.2.3. Discussion of Results 
6.2.3.1. Physical Activity in Stroke 
Low levels of activity have been documented in those hospitalized for an acute illness 
other than stroke (Brown et al., 2004; Brown et al.; Lazarus et al., 1991).  Inactivity during 
hospitalization has been associated with functional decline that necessitated nursing home 
placement even for those who resided in the community prior to hospitalization.  Brown and 
colleagues monitored activity continuously (24 hours/day) using accelerometers and reported 
that older adults recovering from an acute illness in the hospital spend approximately 83% of 
their day lying in bed despite being able to walk independently during their hospital stay (Brown 
et al., 2009). 
Observational studies have examined activity during inpatient stroke rehabilitation and 
have reported high levels of sedentary time (Askim et al., 2014; Bernhardt et al., 2008).  When 
observing activity in 10 minute intervals from 8:00 am to 5:00 pm, patients during in-patient 
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stroke rehabilitation were seen in bed or sitting 76% of the day and standing or walking 23% of 
the day (Bernhardt et al., 2008).  This evidence suggests that during an inpatient rehabilitation 
stay, individuals after stroke are spending a large majority of their time engaging in sedentary 
behavior, which could have a negative impact on functional recovery. 
Prior to the current work, no studies have objectively measured physical activity during 
the hospital stay in the United States.  Accelerometers are a reliable and valid method of 
measuring activity and use very little resources or dedicated work-time out of the schedules of 
hospital staff.  Our results could have profound impact on the future of clinical practice as we 
found our participants to be extremely sedentary and not choosing to move on their own.  We 
reported that people hospitalized with an acute stroke might spend a higher percentage of time 
sedentary than what is reported in the literature for an acute medical illness (Brown et al., 2009).  
Bed rest studies have demonstrated negative vascular adaptations (Bleeker et al., 2004) and loss 
of muscle mass which decreases muscle strength (Kortebein et al., 2007).  Considering patients’ 
low cardiopulmonary fitness levels in acute stroke (Mackay-Lyons,Makrides, 2002), and that the 
low intensity during rehabilitation is not sufficient for cardiopulmonary health (MacKay-
Lyons,Makrides, 2002), efforts to increase physical activity and minimize decline from sedentary 
behavior should be encouraged.  Therefore, using a multidisciplinary team approach to reduce 
sedentary time such as early mobilization during the acute hospital stay may slow the further 







6.2.3.2. Using Non-Exercise Estimation of Peak VO2 in People with Stroke 
Individuals post-stroke are physically inactive, spend small amounts of time walking per 
day (Roos et al., 2012), and have poor aerobic fitness, defined as peak oxygen consumption 
(peak VO2) (Billinger et al., 2012; Gordon et al., 2004; Mackay-Lyons,Makrides, 2002; Macko 
et al., 1997).  Assessing peak VO2 using a metabolic cart with gas analysis is considered the gold 
standard (ACSM, 2010).  Peak VO2 may be an indicator of one’s ability to participate in varying 
levels of activity such as exercise and activities of daily living (ADLs), especially in older adults 
(Billinger et al., 2011; Fleg et al., 2013) and people after stroke (Gordon et al., 2004).  However, 
peak exercise testing is difficult, if not impossible, to conduct during the acute stroke hospital 
stay particularly with shorter lengths of stay especially in the United States.  Therefore, using 
non-exercise measurements, such as prediction equations, to estimate peak VO2 could be a 
simple, low-cost alternative to healthcare providers and especially physical therapists during the 
acute stroke hospital stay. 
Our study was the first to use non-exercise estimation of pre-stroke peak VO2 in those 
with acute stroke and to investigate whether pre-stroke peak VO2 is related to function at 
discharge from the hospital.  Our results showed a weak, non-significant correlation between 
estimated pre-stroke peak VO2 and two of our outcome measures at discharge.  This could be due 
to over- or under-estimation of physical activity prior to stroke since this is a subjective 
assessment.  Additionally, the acute stroke period is a sensitive time where an individual may not 
remember their typical physical activity. It is possible that males and females may account for 
daily physical activity differently.  Therefore, in a post-hoc analysis, we examined whether sex 
differences exist between estimated pre-stroke VO2 peak and functional performance at 
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discharge and found that estimated pre-stroke aerobic fitness was related to function in women, 
but not men. 
Although we did not compare the predicted peak VO2 to a measured VO2, one previous 
study by McAuley and colleagues found that these measures were correlated in older adults with 
chronic disease (McAuley et al., 2011).  The authors used the same non-exercise estimate 
equation as we did.  They investigated the association of the non-exercise estimation of peak 
VO2 measures of aerobic fitness (maximal exercise test and 1-mile timed walk) (McAuley et al., 
2011).  They found that the measure obtained with the estimation equation was significantly 
correlated with measures from the maximal exercise test and the 1-mile timed walk.  McAuley 
suggests that their results serve as evidence that the non-exercise estimate equation has utility in 
other populations, but that future work needs to be done to determine whether relationship exist 
in other domains.  This investigation adds to this literature by describing the relationship of pre-
stroke peak VO2 and measures of function in a small sample of individuals with acute stroke.  
McAuley highlights that assessing aerobic fitness is important in both healthy and diseased 
populations and may give deeper insight into other domains of health and acknowledge that 
exercise testing in older adults and individuals with high cardiovascular risk is difficult because 
of the risks involved, time constraints, and expenses such as obtaining proper equipment, 
personnel, and medical oversight.  Therefore, we believe that there is a need for a short, non-







6.2.3.3. Non-Exercise Estimation of Peak VO2 and IGF-1 Levels 
Insulin-like growth factor-1 (IGF-1) is known to be neuroprotective after middle cerebral 
artery occlusion (MCAO) in animals (Chang et al., 2011; Guan et al., 1993; Guan et al., 1996; 
Zheng et al., 2014) and may even act as a neuronal rescue agent when given through intranasal 
delivery (Guan et al., 1993; Liu et al., 2001).  In animals, when administered through intranasal 
delivery, core lesion size can be reduced up to 94% (Guan et al., 1993) while also improving 
functional status compared to vehicle controls (Zheng et al., 2014).  In humans, those with high 
circulating levels of IGF-1 early after stroke have greater survival rates and fewer impairments, 
tested by the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale 
(mRS), at 3 and 24 months post-stroke compared to those with low IGF-1 levels (Aberg et al., 
2011; De Smedt et al., 2011; Denti et al., 2004).  This suggests that IGF-1 may also have a 
neuroprotective effect in humans. 
Aerobic fitness has been directly related to circulating IGF-1 levels in 846 healthy men 
(Nindl et al., 2011).  Blood was collected in the morning after an overnight fast for the 
quantification of IGF-1.  Individuals then underwent a graded maximal exercise test on a cycle 
ergometer with direct gas analysis to obtain peak VO2.  A repeated squats test was also 
performed to assess leg strength.  Individuals with higher peak VO2 exhibited higher levels of 
circulating baseline IGF-1.  Further, better aerobic fitness was associated with increased 
performance on the repeated squats test, indicating a greater functional performance in the lower 
extremities (Nindl et al., 2011).  Nindl’s study in healthy men could potentially have very large 
implications for individuals post-stroke.  Aerobic fitness prior to a stroke may not only benefit 
overall brain health, but also provide some level of neuroprotection via circulating IGF-1, which 
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has been shown to improve stroke outcomes (Aberg et al., 2011; De Smedt et al., 2011; Denti et 
al., 2004). 
The results of our study showed that estimated pre-stroke peak VO2 was related to 
circulating levels of IGF-1 early after stroke, but not to levels of IGFBP-3.  Further, we sought to 
determine whether individuals with higher than median levels of IGF-1 would have greater 
aerobic fitness (peak VO2) when compared to individuals with lower than median levels, and 
found our hypothesis to be supported by our data. 
 
6.3. Clinical Implications 
6.3.1. Physical Activity in Acute Stroke 
Our results showed that individuals with acute stroke are extremely sedentary and that 
high sedentary time may be detrimental to function within a few days follow stroke.  These 
results have extremely important clinical implications. Education of hospital staff (i.e. 
physicians, nurses, therapists) in the importance of physical activity and mobility for individuals 
during their hospital stay may help to resolve any confusion regarding whether or not to keep 
post-stroke individuals in bed.  Further, education of patients and their families may be 
extremely important.  Oftentimes individuals with stroke may be nervous to move for fear of 
secondary stroke, falling or injury.  Settling these fears and encouraging them to get up and move 
around may help to change their behavior. 
Additionally, there may be a need utilizing “mobility aids”.  These individuals could be 
responsible for safely moving patients from their bed to their chair or helping them walk the 
hallways.  It is no secret that nurses and physicians are incredibly busy with their long list of 
duties and adding mobility aids will help give dedicated attention to this issue.  Mobility aids can 
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also help to encourage individuals to get up if they do not have family member or loved ones 
who regularly visit.  Mobility aids can talk to those that do have family members present about 
helping to encourage their post-stroke loved one to get up and move.  These important clinical 
implications from the results of this study may help to stop perpetuating the sedentary behavior 
before these individuals reach the community. 
 
6.3.2. Using Non-Exercise Estimations of Peak VO2 to Assess Fitness 
As Chapters 3 and 4 describe, non-exercise estimations of peak VO2 are very easy and 
feasible to administer to individuals who are in the very early phases of stroke.  These chapter 
show that the Jurca equation may even be related to functional recovery and a hormone known to 
be neuroprotective.  Often times, exercise specialists and physical therapists use information 
such as peak VO2 to prescribe physical activity and exercise in rehabilitation of disease.  The 
results seen in these two chapters are important because physicians and physical therapist can 
easily use equations such as these to assess fitness very early after stroke and even prescribe 
exercise interventions later in recovery.  After further research, non-exercise equations may 
potentially even be able to use to predict outcomes of stroke recovery.  Finally, peak VO2 
estimation equations could also be used as an education tool for patients in order to teach them 
about aerobic fitness and physical activity. 
 
6.3.3. Fitness and IGF-1 
As mentioned, IGF-1 is a neuroprotective hormone and high levels early after stroke are 
associated with positive outcomes one month and three months following stroke.  In Chapter 4, 
IGF-1 levels are shown to be related to pre-stroke fitness levels.  This is important for clinical 
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practice in that it provides support for physicians to encourage their patients to be physically 
active and maintain their aerobic capacity.  Encouraging individuals, specifically ones with risk 
factors for stroke, to be more physically active or prescribing exercise as medicine, may increase 
baseline IGF-1 levels prior to incidents such as stroke.  Although current literature does not 
describe IGF-1 levels prior to stroke or know if pre-stroke IGF-1 levels are associated with 
recovery, increasing baseline levels could potentially provide neuroprotection in case of cerebral 
injury. 
Chapter 5 discusses the potential relationship between IGF-1 response during the first 
week of stroke and short-term outcomes.  This information could be used in the future by 
clinicians to predict recovery and/or use as a timeline for exercise prescription and or 
interventions related to increasing the uptake of IGF-1 into the brain. 
 
6.4. Limitations 
The authors acknowledge that this collection of investigations was not performed without 
pitfalls and limitations.  Specific limitations have been outlined in individual chapters.  However, 
several broad limitations of the discussed studies are outlined in the following section.  The 
authors made valiant attempts to avoid limitations where possible.  However, with all clinical 
research, some limitations unforeseeable and unavoidable.  Other limitations not described may 
still be relevant to these investigations. 
 
6.4.1. Subject Characteristics and Sample Size 
There are many confounding variables to take into account when considering the size and 
characteristics of our sample.  However, we tried to control for many factors, while also 
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maintaining feasibility of the investigations.  For the examination of physical activity levels on 
the acute stroke unit, we excluded all individuals who were prescribed physician-ordered bed rest 
as to not bias the sample toward sedentary behavior.  Individuals who were assigned bed-rest 
were typically individuals who had either received intravenous tissue plasminogen activator 
(tPA) or individuals who participated in interventional medicine (i.e. clot retrievals, stents, coils, 
or balloons).  Individuals who received tPA had a mandatory 24 hours of bed-rest, while 
individuals who underwent surgical interventions usually had even longer periods of physician-
ordered bedrest.  Often times, after individuals were off their prescribed bed-rest period, they 
were either discharged home or outside the enrollment time-period and no longer eligible for the 
study. 
We did not control for race, ethnicity, socioeconomic status, educational level or 
intelligence.  However, we did not exclude individuals from our studies based on these factors.  
Overall, we had a very demographically diverse sample that closely reflects our goal enrollment 
and the population of the surrounding area (49% male, 59% Caucasian, 12% African American, 
2% Asian, 89% Non-Hispanic) taken from the United States Census Bureau.  The individuals 
enrolled into our studies were: 53% male and 47% female, 72% Caucasian, 17% African 
American, 2% Asian, 2% Pacific Islander, and 7% “other”, and 93% non-Hispanic and 7% 
Hispanic. 
Although our sample is demographically diverse, it was relatively small and a larger 
sample size may reveal further significant results on secondary or less sensitive outcome 
measures.  However, for the purposes of our studies, the necessary sample size was calculated 
and enrolment achieved for each project.  Therefore, we were confident in the number of 
individuals enrolled for these projects. 
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6.4.2. Confounds of Lesion Size and Location 
Lesion size was obtained and calculated from the diagnostic, structural MRI performed 
upon admission for every enrolled individual.  A radiology resident apart of the study team 
calculated lesion volumes using standardize neuroimaging techniques with an ellipsoidal 
assumption of lesion shape.  Limitations of measuring lesion location include the ellipsoidal 
assumption of shape.  Incorrectly assuming an ellipsoidal shape could yield incorrect estimations 
of lesion volume.  However, these are standard practices used in previously published research, 
giving us confidence in using this method.  Further, quality of MRI (i.e. strength of the magnet, 
movement of participant, etc) could also affect lesion measurement.  Finally, in many cases, 
individuals were not experiencing a first time stroke.  Overlap of old infarcts may diminish 
confidence in lesion measurement if the borders are hard to define.  However, trained 
radiologists have the ability to discriminate between acute, subacute and chronic lesions and we 
are confident in ours being able to do so. 
Additionally, general locations of lesions were obtained from the MRI report associated 
with the admitting MRI.  In some cases, statistical analyses were controlled for lesion volume.  
However, no analyses were controlled for lesion location, which could be a potential 
confounding factor.  Location of lesions often have an effect on what type of impairments 
individuals with stroke experience (i.e. motor, speech, vision, coordination).  Therefore, it is 
important to cautiously interpret our results involving functional outcome measures.  
Unfortunately, with the wide variety of lesion locations our participants experienced, our sample 
size was not large enough to account for this variable.  However, few studies of this nature 
consider lesion location due to the infeasibility of recruiting a normally distributed and 
appropriately large sample of individuals. 
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6.4.3. Comorbidities and Medications 
Often people who experience stroke are not without other physical and/or health 
limitations.  For example, 16 individuals in our sample also had Type 1 or Type 2 diabetes.  
Comorbidities such as these can have affected the outcomes investigated.  However, when 
studying individuals with stroke, it is infeasible to exclude for all potential comorbidities.  
Individuals with arthritis, back or other joint pain may have had a difficult time completing 
functional assessments due to their musculoskeletal pain instead of their stroke impairments.  
However, individuals were continuously asked about their pain and comfort during physical 
function testing.  When there were complaints of pain, this was recorded in their file and they 
were allowed to rest until they felt like they could continue without additional distress.  
Individuals with stroke impairments that included deficits in vision or comprehension may have 
had a hard time seeing or understanding the task before them.  However, for studies that involved 
functional assessments, individuals were not enrolled unless they were able to comprehend 
activities and information presented to them in the consent form.  If comprehension was 
questioned, the study team consulted with the physicians and nursing staff and determined if the 
consenting process should continue. 
For studies involving blood draw(s), diabetes and liver function, potential confounding 
factors, were not used as excluding factors.  However, levels of blood glucose, HbA1c, and liver 
enzymes were obtained from the medical record and could be used for post-hoc analyses.  No 
individuals enrolled had levels of liver enzymes out of normal ranges.  All past medical history 
was obtained and recorded in participant files.  This included, but was not limited to, other 
significant medical conditions, medications, and surgical histories.  In addition, blood pressure 
medications, administration of tPA, and diabetes medication could have affected circulating 
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blood protein levels.  However, if medically able to do so, participants were asked to refrain 
from taking their medications beginning midnight before each blood draw.  Finally, individuals 
could not be within 2 hours of receiving tPA when providing a blood sample. 
 
6.4.4. Assessments of Physical Function 
A series of physical function assessments were used in Chapters 2 and 3.  Assessments 
included the Lower Extremity Fugl-Meyer Assessment, Physical Performance Test, 6 Minute 
Walk Test, Timed-Up and Go, and Four Square Step Test.  These assessments were performed in 
serial and typically during an hour to two-hour period.  It is possible that individuals became 
fatigue during this time.  However, individuals were allowed to rest between tasks and between 
assessments for as long as they felt necessary.  Additionally, for assessments performed in the 
corridor outside of the hospital room, individuals were often wheeled out in a wheelchair to limit 
fatigable activity unrelated to the assessments.  If a wheelchair was unavailable or unwarranted, a 
chair was placed near the testing area, but as close to the room as possible so that walking 
distance was minimized and that participants could rest while explanation of the assessment was 
given.  Further, it was not uncommon for individuals to complain of a headache.  Performing 
assessments of physical function was avoided during times of headache so that individuals could 
perform their best.  There were several occasions where performing assessments during 
headaches was unavoidable.  However, headache and pain was noted in the file where 
appropriate. 
Distractions during functional testing were limited.  All assessments performed in the 
participants’ rooms were done so with the door closed.  Nurses were alerted that testing was 
being performed so that they could limit the amount of people entering the room during that 
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time.  Hospital staff was educated by the study team to not distract and speak with the 
participants during testing in the corridor outside participants’ rooms.  Orange cones were placed 
around the testing area to alert people to go around.  Subjects were instructed to limit 
conversation with both the study team and other individuals walking by.  In many cases, family 
members or loved ones were present and wanted to watch testing.  Study team members allowed 
family members and loved ones to stay in the room or come into the corridor as long as they did 
not talk the participant during testing.  It is possible that in the presence of family/loved ones, 
individuals either had more or less motivation to perform well.  They may feel more pressure to 
perform well if others are watching or less motivated to participate if they are wanting to be with 
their visitor instead.  Finally, motivation of the participant may vary day to day depending on the 
amount of sleep they acquired the night before, the amount of activity they already did during 
that day, and/or how they were feeling physically and emotionally at that moment. 
 
6.4.5. Assessment of Physical Activity 
As with any wearable device, there are several potential limitations. Individuals were 
instructed to remain wearing the tri-axial accelerometers unless they really needed to remove 
them for comfort or otherwise.  These devices are water-resistant in 1 meter of water for up to 30 
minutes, so participants were informed that removal during showers or bathing was not 
necessary.  An individual from the study team checked on participants daily to make sure they 
were feeling comfortable wearing the accelerometers and to ask whether they had removed the 
device during the last 24 hours.  Occasionally, a sock or gauze was placed between the skin and 
the accelerometer to provide additional comfort.  If any reports of device removal were made, a 
note was put in the file and that time frame was deleted from a copy of the electronic file.  
134 
 
Further, it is possible that participants failed to report device removal due to failure of 
remembering or nervousness of admitting. In one case, accelerometers were removed for an 
extended period of time.  Therefore, that participant was not used in data collection. 
Although we found our participants to be extremely sedentary, there may still have been an 
effect of knowing that they are being “watched”.  If one knows they are being monitored for 
physical activity, it is likely that they will perform greater amounts of activity than what they 
normally would have otherwise.  In addition to this, individuals with family members or visitors 
present may have been encouraged to move more than individuals who did not have visitors 
present.  Finally, because of the nature of tri-axial accelerometers, it is possible that activity may 
have been artificially inflated due to transportation of participants by either hospital bed or 
wheelchair.  The accelerometers would not have recognized this acceleration as mobility due to 
outside forces.  However, in the proprietary software, it is possible to break down activity by 
each plane of movement and identify at what times acceleration was rapidly occurring in only 
one plane (i.e. being pushing forward in a wheelchair, moving up or down in an elevator). 
 
6.4.6. Assessment of Non-Exercise Estimation 
Several limitations could be attributed to the Jurca non-exercise estimation of pre-stroke 
peak VO2.  For example, one component of the equation is the self-selected measure of physical 
activity.  It is possible that individuals post-stroke could have a hard time remembering or 
reporting the amount of activity they performed in a typical week prior to their stroke, resulting 
in an over- or under-estimation of peak VO2.  Further, individuals may be embarrassed by their 
true amount of activity and over-estimate it in order to compensate. 
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This estimation equation has not yet been validated specifically in stroke.  However, cross-
validation has occurred in older adults who possess 1-6 cardiovascular risk factors, giving us 
confidence to use this measure in individuals with stroke.  Additionally, it was previously 
unknown whether resting heart rate remained unchanged from pre- to post-stroke.  However, our 
sample subset showed that resting heart rate was not significantly different from recorded resting 
heart rate of an outpatient visit prior to stroke to resting heart rate recording during the hospital 
stay for acute stroke.  Finally, our results showed that this equation may not predict peak VO2 
very well in men and therefore, future studies should investigate the use of the Jurca equation in 
individuals with stroke further.  
 
6.4.7. Quantification of IGF-1 and IGFBP-3 
Finally, there are several potential limitations of blood collection and analysis.  First, 
circulating levels of IGF-1 and IGFBP-3 are known to be affected by time of day and nutritional 
status.  Therefore, samples collected at different times or under different lengths after meals may 
be variable in protein levels.  However, these variations were limited by enforcing a very strict 
sampling period in our participants.  All samples were obtained during the hours of 7:30 am and 
9:30 am.  Further, individuals were told to fast from food and drink (with the exception of water) 
beginning at midnight before sampling.  Medications were also held when medically able to do 
so.  Further, hydration of participants may have an effect on the ability to draw blood.  In very 
few cases, we were only able to draw a small amount of blood.  The length of time from draw to 
being frozen may have an effect on protein viability.  However, all samples were placed on ice 
immediately after being drawn.  Samples were transported to the laboratory for processing and 
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frozen within one hour of collection.  All samples were processed in the same manner with the 
same equipment. 
Variations in assaying could introduce additional error.  Kits for protein concentration 
outline the number of allowable freeze/thaw cycles.  No samples were frozen and thawed more 
than the recommended times and most samples were only thawed once.  Further, errors in 
assaying due to inexperience and lack of skill may lead to inaccurate results.  However, all 
assays were performed with a standard curve of an r of .98 or greater.  Internal controls provided 
by kits were used for all assays and were well within acceptable ranges.  Finally, concentrations 
of proteins could be influenced by physical activity level of individuals immediately prior to 
blood sampling, age, gender, body mass index (BMI), and diet. 
 
6.5. Future Directions 
The investigations undertaken by this body of work have important implications for 
future studies.  The following section discusses the future directions that are important to the 
field of research as outlined by the results presented previously. 
 
6.5.1. Physical Activity in Acute Stroke 
In Chapter 2 it was shown that individuals admitted to the hospital with acute stroke 
engage in very little physical activity.  Further, the amount of sedentary behavior may be related 
to function on discharge from the hospital, regardless of functional performance at admission.  
These results warrant future studies to examine how physical activity during the hospital stay 
relate to long term follow up of function.  That is to say, do people who spend less time 
sedentary perform better on functional assessments 6 months or 1 year after discharge from the 
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hospital?  Further, do individuals who perform more physical activity during the hospital stay 
continue performing more activity as post-stroke individuals living in the community compared 
to post-stroke individuals who performed less activity in the hospital?  Finally, is there a 
minimum amount of activity needed in order to see significant benefits? 
 
6.5.2. IGF-1 and Objective Measures of Physical Function 
Chapters 4 and 5 discuss IGF-1, a neuroprotective hormone, and its relationship to 
aerobic fitness and short-term stroke outcomes.  Current literature describes early levels of IGF-1 
and how it relates to survival and independence later in recovery.  This study adds to the field of 
knowledge by describing IGF-1’s relationship to estimated fitness, IGF-1’s response during the 
first week of stroke, and how IGF-1’s response is related to short-term outcomes.  Future studies 
should examine how IGF-1 levels and IGF-1 response early after stroke are related to objective 
measures of function during stroke recovery.  This will provide more in-depth detail on how 
IGF-1 can affect physical function both in the upper and lower extremities.  Using assessments 
such as the ones performed in Chapters 2 and 3 to assess IGF-1’s relationship to function can 
give important insight into neuroprotection and recovery. 
 
6.5.3. Exercise Intervention Effects on IGF-1 Levels and Recovery 
Exercise has shown to increase levels of IGF-1 and its uptake into the brain from the 
periphery in healthy humans and animals with experimental stroke.  In addition to this, the 
promising results from this collection of work that outlines the relationship of IGF-1 to estimated 
pre-stroke fitness raise many unanswered questions.  Future studies can investigate whether IGF-
1 can be increased from exercise interventions in individuals with stroke and if so, what 
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frequency, intensity, time, and type of exercise elicits most beneficial changes in IGF-1 levels.  
In addition, future research should study how IGF-1 increases due to physical activity and 
exercise related to improvements in function during stroke recovery. 
 
6.5.4. Intranasal Administration of IGF-1 
Animal models of stroke show that administration of IGF-1 after insult through intranasal 
delivery provides benefits to lesion size and function.  IGF-1 has been administered in healthy 
adults to study how it affects exercise performance.  However, administration of IGF-1 has not 
been used in individuals who experienced stroke.  Large clinical trials using IGF-1 as a rescue 
agent should determine if there are also beneficial effects in humans.  If neuroprotective effects 
are seen through intranasal delivery, dosing and time of administration should also be studied. 
 
6.6. Conclusions 
In conclusion, this body of work describes physical activity and sedentary levels of 
individuals with acute stroke while they are in the hospital and how activity relates to functional 
status at discharge.  Further, discussion of using non-exercise peak VO2 in the hospital setting 
determined that measures such as these are practical and easy to use and may potentially have a 
relationship to both functional recovery and neuroprotection.  Our results showed that 
individuals with acute stroke who had higher pre-stroke fitness levels had higher levels of IGF-1 
compared to individuals with acute stroke with lower pre-stroke fitness levels.  Finally, this 
collection of studies revealed that decreases in IGF-1 levels are related to positive short-term 
outcome during stroke recovery.  This is the first investigation to study how the response of IGF-
1 during the first week relates to outcomes and warrants future research.  The presented work is 
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novel and significant in that it provides objective measures of activity and neuroprotection very 
early after stroke and new evidence for the use of easy-to-administer assessments of fitness.  
These studies set important groundwork for additional research to provide greater detail accounts 
of the interaction of fitness, physical activity, IGF-1 levels, and functional recovery. 
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